Graphical abstract

Keywords: Mitochondrial dysfunction, Oxidative stress, Necroptosis, Pyroptosis, PANoptosis
Highlights
-
•
Mitochondrial dysfunction and oxidative stress are key drivers of neurodegeneration.
-
•
PANoptosis exacerbates neuronal dysfunction and cell death in neurological diseases.
-
•
Mitochondrial dysfunctions and oxidative stress are key inducers of PANoptosis activation.
-
•
Mitochondria-targeted antioxidants hold significant potential for inhibiting PANoptosis.
-
•
PANoptosis inhibition demonstrates multiple neuroprotective effects in neurological disease.
Abstract
Background
Mitochondrial oxidative stress is a key driver of neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, and spinal cord injury, promoting neuronal dysfunction and degeneration through multiple pathways. PANoptosis, a recently characterized regulated cell death pathway integrating pyroptotic, apoptotic, and necroptotic signaling, exacerbates neuroinflammation and accelerates neuron loss. Emerging evidence reveals the important role of mitochondrial oxidative stress in inducing PANoptosis through complex mechanisms associated with reactive oxygen species overproduction, mitochondrial DNA damage, and impaired mitochondrial dynamics.
Aim of review
This review aims to summarize current knowledge on the mechanisms and roles of PANoptosis in neurological diseases, with a focus on its interplay with mitochondrial oxidative stress.
Key scientific concepts of review
This review provides insight into the intricate crosstalk between mitochondrial oxidative stress and the activation of PANoptosis, particularly through caspase activation, necroptotic signaling, and pyroptotic pathways. Furthermore, we highlight emerging therapeutic interventions that target these mechanisms. These strategies have shown promise in attenuating neuroinflammation and neuronal death, offering hope for the development of targeted therapies to address the complex pathophysiology of neurological diseases.
Introduction
Mitochondria serve as the powerhouse of the cell and are involved in regulation of metabolic homeostasis and cell death [1]. Reactive oxygen species (ROS) are byproducts of mitochondrial respiration that act as signaling molecules. Excess ROS can lead to cellular dysfunction and damage [2]. Neurons are particularly susceptible to oxidative stress, primarily because of their elevated metabolic requirements and restricted regenerative capabilities. Mitochondrial dysfunction leads to neuronal energy deficits and ROS overproduction, resulting in neuronal dysfunction and death. For example, oxidative stress promotes amyloid-beta (Aβ) plaques and Tau tangles accumulation, thereby impairing neuronal and synaptic function in Alzheimer’s disease (AD) [3]. Similarly, in Parkinson’s disease (PD), impaired mitochondrial dynamics contribute to dopaminergic neurodegeneration [4]. Impaired mitochondrial integrity also drives oxidative damage to neurons following spinal cord injury [5]. Upon mitochondrial oxidative stress, these diseases are often exacerbated by neuroinflammation and neurodegeneration, further complicating the disease pathogenesis.
Recent discoveries have linked mitochondrial oxidative stress to neurological diseases through PANoptosis. PANoptosis is an inflammatory regulated cell death that integrates pyroptotic, apoptotic, and necroptotic pathways, as indicated by its acronym PAN [6]. It is triggered by the PANoptosome, a multiprotein complex incorporating regulators from all three death mechanisms [7]. The discovery of PANoptosis reveals how cells integrate different cell death pathways into a coordinated response to internal and external stimuli, providing a potential therapeutic strategy to simultaneously modulate multiple pathways [8], [9]. The mechanisms and roles of PANoptosis in neurological diseases are increasingly recognized, such as AD, spinal cord injury, and glaucoma, contributing to neuron loss and disease progression [5], [10], [11].
In this review, we first highlight the key mechanisms of mitochondrial dysfunctions and oxidative stress in triggering neuroinflammation and neurodegeneration. We then summarize the intricate relationship between mitochondrial oxidative stress and PANoptosis, and their roles in driving neurological diseases. Finally, we discuss the therapeutic potential of targeting mitochondrial oxidative stress and PANoptosis to develop new strategies for treating neurological diseases.
Mitochondrial dysfunctions induce oxidative stress and cellular damage
Dysfunction in mitochondria drives oxidative stress and cell injury via convergent pathways. This section outlines the key mechanisms involved, beginning with core bioenergetic failures-electron transport chain dysfunction, calcium overload, and mitochondrial DNA damage-that directly increase ROS. It then examines how the collapse of mitochondrial quality control- impaired mitochondrial dynamics, defective mitophagy, and deficient biogenesis-amplifies this damage (Table 1). Together, these disruptions reinforce each other to sustain mitochondrial dysfunctions and oxidative injury to induce cellular damage.
Table 1.
Key mechanisms of mitochondrial quality control and its effects on oxidative stress.
| Component | Type | Regulator | Physiological function | Effect on oxidative stress | Ref |
|---|---|---|---|---|---|
| Mitochondrial Dynamics | Fission | DRP1, FIS1, Mff | Mitochondrial fission divides the organelle to facilitate distribution, quality control, and removal of damaged components | Excessive fission leads to fragmented, dysfunctional mitochondria with impaired ETC, increasing electron leakage and ROS | [1], [18] |
| Fusion | MFN1/2, OPA1 | Mitochondrial fusion merges organelles to optimize energy production and repair damage through content sharing | Defective fusion prevents repair of damaged mitochondria, allowing persistent ETC dysfunction and sustained ROS production | [20], [80] | |
| Mitophagy | Ubiquitin‑dependent mitophagy | PINK1, Parkin | PINK1/Parkin‑dependent mitophagy selectively removes damaged mitochondria to maintain cellular health | Defective PINK1/Parkin‑dependent mitophagy leads to the accumulation of ROS-producing damaged mitochondria, which become a persistent source of oxidative stress | [22], [116] |
| Receptor‑dependent mitophagy | BNIP3, BNIP3L/NIX, FUNDC1 | Receptor‑dependent mitophagy employs specific outer‑membrane receptors to target and degrade superfluous or damaged mitochondria | Impaired receptor‑dependent mitophagy disrupts the clearance of defective mitochondria, thereby exacerbating oxidative damage | [23] | |
| Mitochondrial Biogenesis | PGC-1α, NRF-1/2, TFAM | Mitochondrial biogenesis generates new mitochondria to replenish the functional pool and replace damaged organelles | Deficient mitochondrial biogenesis compromises ETC integrity, increases electron leakage, weakens antioxidant capacity, and triggers bioenergetic failure | [24], [26] |
Abbreviations: Drp1, dynamin-related protein 1; FIS1, Fission 1; Mff, mitochondrial fission factor; ETC, electron transport chain; ROS, reactive oxygen species; MFN1/2, Mitofusin 1/2; OPA1, optic atrophy protein 1; PINK1, PTEN-induced putative kinase 1; BNIP3, BCL2/adenovirus E1B 19 kDa protein‑interacting protein 3; BNIP3L, BNIP3-like; FUNDC1, FUN14 domain‑containing protein 1; PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator-1α; NRF-1/2, nuclear respiratory factor-1/2; TFAM, mitochondrial transcription factor A; SOD2, superoxide dismutase 2.
Electron transport chain dysfunction
Mitochondria generates adenosine triphosphate (ATP) via oxidative phosphorylation through the electron transport chain, which is embedded in the inner membrane [1] (Fig. 1). The electron transport chain comprises four main enzyme complexes that transfer electrons to oxygen. When electrons escape this chain and interact with oxygen, ROS are produced, including hydrogen peroxide (H2O2), hydroxyl radicals, and superoxide anion [12]. Under normal conditions, ROS production is tightly regulated and remain essential for normal cell function. Mitochondria also possess antioxidant defense mechanisms, such as superoxide dismutase (SOD) and catalase, which work to neutralize ROS and prevent cellular harm [13]. When electron transport chain function is impaired, electron flow slows, increasing electron leakage to oxygen [12]. Excessive ROS damages proteins, lipids, and mitochondrial DNA, exacerbating electron transport chain dysfunction in a vicious cycle.
Fig. 1.

Mitochondrial ROS generation and oxidative stress. Mitochondria are the primary source of reactive oxygen species (ROS) generation. Within the electron transport chain (ETC), electron leakage from complexes I and III generates superoxide (O2•−), which is then converted to hydrogen peroxide (H2O2) by mitochondrial superoxide dismutase (SOD2). Monoamine oxidase (MAO) metabolizes neurotransmitters like norepinephrine, producing H2O2 as a byproduct. NADPH oxidases (NOX), specifically NOX1/2 and NOX4 isoforms, also contribute significantly to ROS production. NOX1/2, activated by cytosolic subunits (p67, p47, p40, RAC), generates O2•− at the plasma membrane, which is subsequently converted to H2O2. NOX4, located on intracellular membranes including mitochondria, produces H2O2 directly. p66Shc, a redox enzyme, amplifies mitochondrial ROS generation by catalyzing electron transfer from cytochrome c to oxygen, generating H2O2. Peroxisomes represent an additional source of H2O2 via oxidative metabolic reactions. The resulting ROS accumulation leads to oxidative stress, causing DNA damage, lipid peroxidation, inflammation, and activation of cell death pathways. Created with BioRender.com.
Mitochondrial calcium overload
Calcium ions are essential for intracellular signaling and mitochondrial function [14]. Mitochondrial calcium overload occurs when excessive calcium accumulates through mitochondrial membrane channels [8], [15]. This directly impacts mitochondrial respiratory chain complexes (such as complexes I and III), disrupting energy synthesis and causing incomplete electron transfer. As a result, some electrons directly combine oxygen molecules, generating superoxide anions and hydroxyl radicals [15]. In addition, calcium overload interferes with the intracellular antioxidant system, exacerbating oxidative stress. For example, it inhibits glutathione (GSH) synthesis, suppresses the activity of antioxidant enzymes like SOD through calcium-calmodulin-dependent enzyme activity, and inhibits catalase (CAT). Together, these effects reduce the cell’s ability to eliminate superoxide anions, leading to harmful oxidative stress [14].
Mitochondrial DNA damage
The mitochondrial DNA (mtDNA) lacks histone protection, making it prone to mutations and deletions [16]. These mutations can disrupt electron transport chain proteins, thereby reducing electron transfer efficiency, limiting proton pumping, lowering oxidative phosphorylation efficiency, and impairing ATP synthesis [17]. This process results in increased electron leakage and the generation of excess ROS, which exacerbates mtDNA damage and mitochondrial dysfunction [12]. In addition, mtDNA damage can activate apoptotic pathways through Bcl-2 family proteins and caspase activation. These processes help eliminate damaged cells, but when damage accumulates, intensified oxidative stress can induce uncontrolled cell death and tissue damages [17].
Impaired mitochondrial dynamics
Mitochondria undergoes continuous fusion and fission processes, which require strict quality control to maintain their morphology, number, and function [1]. Imbalance in these processes result in accumulation of dysfunctional mitochondria, causing energy deficits and ROS overproduction. Mitochondrial fission involves the division of mitochondria into smaller fragments, primarily regulated by Dynamin-related protein 1 (DRP1) [18]. Adaptor proteins such as Fission 1 (FIS1) and mitochondrial fission factor (Mff) recruit DRP1 to the outer mitochondrial membrane, thereby driving membrane scission. Mitochondrial fusion unites individual mitochondria to form larger, interconnected networks [19]. This process is primarily regulated by mitofusin 1/2 (MFN1/2) and optic atrophy protein 1 (OPA1) [20]. Excessive fission, mediated by increased DRP1 recruitment, leads to accumulated mitochondrial fragmentation, resulting in energy deficits, calcium overload, and excessive ROS production [1]. Conversely, defective mitochondrial fusion caused by loss of MFN1/2 or OPA1 prevents the repair of damaged mitochondria, further exacerbating dysfunction and oxidative damage [21]. Therefore, balancing fission and fusion is essential for cellular homeostasis.
Defective mitophagy
Mitophagy removes damaged mitochondria through selective autophagic clearance, serving as a key quality control mechanism. The canonical mitophagy pathway is driven by PTEN-induced putative kinase 1 (PINK1) and Parkin pathway, which marks damaged mitochondria for autophagic degradation [22]. The PINK1-Parkin-independent mitophagy is mediated by other outer membrane receptors like BCL2/adenovirus E1B 19 kDa protein‑interacting protein 3 (BNIP3), BNIP3-like (BNIP3L/NIX) proteins, and FUN14 domain‑containing protein 1 (FUNDC1) [23]. Additionally, general autophagy also helps to non-specifically clear damaged cellular components, including impaired mitochondria [24]. In parallel, the mitochondrial unfolded protein response (UPRmt) assists in repairing or removing misfolded proteins by increasing the expression of chaperone proteins and proteases, thereby restoring mitochondrial proteostasis [25]. When these processes are impaired, dysfunctional mitochondria accumulate, resulting in elevated ROS production, intensified oxidative stress, and ultimately cellular dysfunction and death.
Mitochondrial biogenesis deficiency
Mitochondrial biogenesis produces new mitochondria to fulfill cellular energy needs and replace damaged organelles. This process is mediated by peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α), which activates nuclear respiratory factors (NRF-1/2) and mitochondrial transcription factor A (TFAM) to stimulates the transcription of oxidative phosphorylation (OXPHOS) genes [12], [24], [26]. Impairment of biogenesis directly promotes oxidative stress through multiple converging mechanisms. Reduced PGC-1α activity inhibits the synthesis of electron transport chain subunits, resulting in structurally defective supercomplexes that increase electron leakage and superoxide production [27]. Concurrently, the resulting bioenergetic deficit from reduced mitochondrial mass and capacity triggers compensatory metabolic shifts, such as elevated glycolysis [28]. This raises cellular reducing equivalents that overload the impaired electron transport chain, fueling further ROS generation. Moreover, downregulation of PGC‑1α weakens mitochondrial antioxidant defense by lowering the expression of SOD2, permitting ROS accumulation and progressive oxidative damage [27].
Taken together, mitochondrial dysfunction is a primary driver of oxidative stress and cellular damage, initiated through multiple interconnected mechanisms. Impairment of the electron transport chain, calcium overload, and mtDNA damage directly increase ROS production. These defects are then amplified by the collapse of mitochondrial quality control: imbalanced fission/fusion leads to fragmented, ROS-producing organelles; defective mitophagy allows damaged mitochondria to persist; and deficient biogenesis reduces functional capacity while weakening antioxidant defenses. Together, these failures create a self-reinforcing vicious cycle of rising ROS, escalating mitochondrial damage, bioenergetic crisis, and ultimately driving cellular dysfunction and cell death.
Mitochondrial oxidative stress triggers neuroinflammation and neurodegeneration
Mitochondrial oxidative stress drives the pathogenesis of multiple neurological diseases. In this section, we highlight the roles of mitochondrial oxidative stress in these diseases and discuss the molecular mechanisms connecting mitochondrial oxidative stress to neuroinflammation and neurodegeneration (Fig. 2).
Fig. 2.

Mitochondrial oxidative stress triggers neuroinflammation and neurodegeneration. Mitochondrial oxidative stress serves as an important driver of neuroinflammation and neurodegeneration. It disrupts PINK1/Parkin-mediated mitophagy pathway, leading to the accumulation of dysfunctional mitochondria. This results in a vicious cycle of oxidative damage that drives neuroinflammation and neurodegeneration. Dysfunctional mitochondria, characterized by impaired dynamics and bioenergetic failure (reduced ATP levels), lead to the release of mitochondrial DNA (mtDNA) and cytochrome c (Cyt C). The released mtDNA activates the cyclic GMP-AMP synthetase-stimulator of interferon genes (cGAS-STING) pathway, inducing interferon production and neuroinflammation. Concurrently, Cyt C initiates the intrinsic apoptotic pathway through apoptosome formation (Apaf-1/caspase-9) and subsequent caspase-3 activation, ultimately promoting neuronal cell death. Created with BioRender.com.
Mitochondrial oxidative stress in Alzheimer’s disease
Alzheimer’s disease (AD), one of the most prevalent forms of dementia, is characterized by progressive cognitive decline and neuronal loss [29]. Accumulation of amyloid-beta (Aβ) plaques and hyperphosphorylated Tau tangles are the pathological hallmarks of AD. Growing evidence indicates that mitochondrial oxidative stress drives the progression of AD. [28], [30].
NADPH oxidase 4 (NOX4) serves as an upstream molecular target for mitochondrial oxidative stress in AD. In AD brains, elevated NOX4 triggers excessive production of mitochondrial ROS [3]. This overproduction of ROS results in lipid peroxidation, marked by elevated levels of 4-hydroxy-2-nonenal (4-HNE) and malondialdehyde (MDA), alongside enhanced iron accumulation and cytotoxicity in astrocytes. These processes exacerbate oxidative damage, promoting astrocyte death and worsening AD pathology. Moreover, thioredoxin-interacting protein (TXNIP; a thioredoxin inhibitor), upregulated by the Aβ-receptor for advanced glycation end products (RAGE) interaction, exacerbates oxidative stress through its inhibition of antioxidant defenses in Aβ(1–42)-induced AD mice [30]. In 3xTg-AD mice, TXNIP levels are significantly elevated, and there is a marked increase in Tau and phosphorylated Tau (p-Tau), suggesting a strong correlation between TXNIP upregulation and abnormal Tau accumulation [29]. Taken together, these findings indicate that mitochondrial oxidative stress is critical to pathological mechanism in AD, where it exacerbates Tau pathology and neuron death.
Mitochondrial oxidative stress in Parkinson’s disease
Parkinson’s disease (PD) involves the dopaminergic neuron loss in the substantia nigra, resulting in motor impairments [31]. Dopaminergic neurons exhibit heightened vulnerability to mitochondrial oxidative stress, owing to their elevated energy requirements and dopamine’s propensity for redox cycling [32], [33]. In addition, abnormal accumulation of α-synuclein forms aggregates that exacerbate oxidative stress and impair neuronal function in PD. Rotenone, as a mitochondrial complex I inhibitor, can exacerbates Parkinson's disease by inducing mitochondrial dysfunction and oxidative stress through inhibition of mitochondrial complex I [34].
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) has demonstrated antioxidant effects in rotenone-induced PD models. It alleviates oxidative damage by reducing α-synuclein accumulation in the midbrain and striatum, decreases ROS production, restoring antioxidant enzymes activity, and lowering MDA levels [35]. Additionally, EMPA suppresses oxidative stress-induced inflammation by reducing the levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in in rotenone-induced PD rats [36]. It also improves antioxidant capacity and mitochondrial function by restoring SIRT-1 and PGC-1α levels, thereby mitigating oxidative damage and slowing neuronal degeneration [31], [35]. Given these properties, EMPA represents a promising therapeutic candidate for mitigating oxidative stress-mediated damage in in PD.
Keeney et al. also found that increased LRRK2 kinase activity (pS1292-LRRK2) exacerbated oxidative stress and excessive mtROS in the PD patient-derived lymphoblastoid cells and rotenone-induced PD model [32]. LRRK2 amplifies oxidative stress by phosphorylating p47phox (a NOX2 subunit) at Ser345, promoting its translocation to gp91phox and activating NOX2 [32]. This enhances ROS production, induces lipid peroxidation (4-HNE accumulation), and accelerates oxidative neuronal damage. The LRRK2 inhibitor PF360 also suppressed NOX2 activation and lipid peroxidation in substantia nigra dopaminergic neurons, alleviating oxidative stress-induced neurodegeneration in cell and animal models of PD [2].
Collectively, these findings underscore mitochondrial oxidative stress as an inducer of dopaminergic neuron vulnerability, contributing to progression of neuroinflammation and neurodegeneration in PD.
Mitochondrial oxidative stress in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a selective degeneration of both upper and lower motor neurons, resulting in progressive muscle weakness and atrophy [37]. Oxidative stress induces macromolecular damage in ALS through protein oxidation, lipid peroxidation, and DNA oxidative lesions [38]. The 43 kDa TAR-DNA binding protein (TDP-43) is a major component of pathological aggregates in ALS, present across both familial and sporadic disease forms [39]. Oxidative stress triggers nuclear-to-cytoplasmic translocation of TDP-43, facilitating its aggregation in the cytosol. In an ALS model induced by TDP-43, it upregulates the expression of mitochondrial genes by sequestering miRNAs and co-aggregates with mitochondrial proteins, isolating them from their normal function [40]. This leads to an imbalance in mitochondrial protein levels, ultimately disrupting mitochondrial homeostasis. Mitochondrial imbalance results in increased ROS, which further promotes the cleavage and aggregation of TDP-43, creating a positive feedback loop that drives ALS pathogenesis.
In SOD1-G93A mice (a classic ALS model) and Neuroblastoma Spinal Cord-34 (NSC-34) cell models, the SOD1 mutation disrupts mitochondrial membrane potential and ATP synthesis, weakens cellular energy supply, and causes the mitochondrial dysfunction [37]. Additionally, this mutation increases mtROS levels, further amplifying oxidative damage and creating a pathogenic cycle. Meanwhile, the SOD1-G93A mutation impairs the synthesis of GSH and weakens ROS scavenging capacity. In particular, the decline in mitochondrial GSH levels further disrupts mitochondrial function and promotes apoptosis [41]. Furthermore, reduced activity of NRF2, a key antioxidant regulator, in ALS patients and animal models decreases expression of antioxidant genes, exacerbating neuronal vulnerability to oxidative stress and accelerating neuronal degeneration [38]. The interplay of these mechanisms ultimately leads to motor neuron death, muscle atrophy, and significantly shortened ALS patient survival [41].
Therefore, mitochondrial oxidative stress and resultant dysfunction form a pathogenic cycle with TDP-43/SOD1 in ALS, disrupting proteostasis and redox balance to drive motor neuron degeneration.
Mitochondrial oxidative stress in traumatic brain injury
Traumatic brain injury results from external mechanical forces to the head, producing structural damage and dysfunction [42]. In a mouse model of traumatic brain injury, oxidative stress levels increase significantly, with excessive ROS disrupting membrane potential stability, and triggering neuron loss [43]. Copper ions are important for regulating intracellular redox reactions, particularly by interacting with SOD1 to modulate ROS production and clearance [44]. Additionally, the redox activity of copper ions in the free state can generate ROS, which may exert cytotoxic effects. Studies have shown that Atox1, a copper chaperone protein, was downregulated following traumatic brain injury, disrupting the copper homeostasis and exacerbating oxidative stress [42]. Atox1 overexpression also enhances antioxidant capacity and restores mitochondrial homeostasis, thereby reducing apoptosis and promoting neurological recovery in mice models. Thus, mitochondrial oxidative stress is an important secondary injury mechanism in traumatic brain injury, disrupting copper homeostasis and triggering neuron death.
Mitochondrial oxidative stress in multiple sclerosis
Multiple sclerosis is a chronic autoimmune central nervous system disorder characterized by immune-mediated demyelination, sustained neuroinflammation, and progressive neurodegeneration [45]. Normally, the phosphatidylinositol 3-kinase (PI3K)/Akt activation suppresses oxidative stress through phosphorylating and inactivating glycogen synthase kinase-3β (GSK-3β) [46]. However, in experimental autoimmune encephalomyelitis (EAE) mice (a classical multiple sclerosis model), reduced levels of inhibitory GSK-3β lead to GSK-3β hyperactivation, resulting in axonal demyelination, neuronal apoptosis, and neuroinflammation [47]. Additionally, GSK-3β overexpression in multiple sclerosis aggravates oxidative stress and neuroinflammation [46]. In the EAE model, excessive activation of GSK-3β also may lead to decreased NRF2 levels and reduced SOD expression, thereby weakening antioxidant capacity and exacerbating oxidative stress damage [13]. A novel GLP-1 receptor agonist, Semaglutide, can inhibit the activity of GSK-3β and improve NRF2 expression, thereby enhancing SOD levels and the antioxidant capacity. Furthermore, GSK-3β inhibition can also reduce NF-κB and TNF-α expression, thereby alleviating neuroinflammation in EAE mice [45]. Therefore, Semaglutide provides a novel intervention strategy through the PI3K/AKT/GSK-3β pathway for multiple sclerosis treatment. Collectively, these findings reveal that mitochondrial oxidative stress in multiple sclerosis is closely linked to GSK-3β overactivation, which impairs antioxidant response and fuels neuroinflammation.
Mitochondrial oxidative stress in Huntington’s disease
Huntington’s disease is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansion in the HTT gene, resulting in production of toxic mutant huntingtin protein (mHTT) [48]. Studies have shown that mHTT interacts with the TIM23 mitochondrial protein import complex, impairing normal protein import, thereby disrupting mitochondrial homeostasis and exacerbating oxidative stress in the patients [49]. Excessive ROS generation contributes to mitochondrial dysfunction by inducing oxidative mtDNA damage and compromising DNA repair systems in Huntington’s disease [48]. Furthermore, oxidative stress-induced mitochondrial damage leads to cytosolic mtDNA leakage, which activates the cyclic GMP-AMP synthetase-stimulator of interferon genes (cGAS-STING) pathway, thereby exacerbating neuroinflammation. Melatonin is an endogenous mitochondrial-targeted antioxidant that maintains mitochondrial homeostasis and function [50]. Its supplementation exerts neuroprotective effects in Huntington’s disease by alleviating oxidative stress and neuroinflammation. Thus, mitochondrial oxidative stress arises from mHTT-induced import defects and mtDNA damage, creating a self-reinforcing loop of dysfunction and neuroinflammation.
Taken together, mitochondrial oxidative stress is a key contributor to the pathological progression of various neurological diseases. Excessive ROS production directly damages neurons and accelerates neurodegenerative processes by inducing protein aggregation, disrupting mitochondrial function, and activating inflammatory pathways.
PANoptosis, an integrated cell death pathway, is mediated by mitochondrial oxidative stress
Recent advances in cell death research have revealed a novel form of regulated cell death called PANoptosis, which integrates features of pyroptotic, apoptotic, and necroptotic pathways (Fig. 3) [6]. Unlike individual pathways, PANoptosis is regulated by PANoptosome, a dynamic multiprotein complex that scaffolds key regulators from apoptotic, necroptotic, and pyroptotic pathways [7]. PANoptosis holds particular significance in mitochondrial oxidative stress, as excessive ROS production and mitochondrial dysfunction can initiate and amplify this multifaceted cell death process (Table 2) [5], [8], [16], [51].
Fig. 3.

PANoptosis is regulated by the PANoptosome complex and integrates features of apoptosis, necroptosis, and pyroptosis pathways. PANoptosis represents an integrated cell death pathway regulated by the PANoptosome complex, a multiprotein complex that converges proteins such as NLRP3, ASC, Caspase-1 (pyroptosis), caspase-8 (apoptosis), and RIPK1, RIPK3 (necroptosis) to coordinate simultaneous activation of these pathways. Stimuli such as virus, bacteria, damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), are detected by upstream sensors (ZBP1, AIM2, NLRC5), triggering PANoptosome formation. This leads to the simultaneous activation of all three pathways: gasdermin D-dependent pyroptotic pore formation, caspase-mediated apoptotic cleavage, and MLKL-driven necroptotic membrane rupture, leading to lytic cell death and the release of pro-inflammatory mediators (IL-1β, IL-18, DAMPs). PANoptosis thus combines these potent cell-killing mechanisms with amplified inflammatory responses. Created with BioRender.com.
Table 2.
Key regulators involved in mitochondrial oxidative stress and PANoptosis.
| Regulator | Involvement in mitochondrial oxidative stress | Involvement in PANoptosis | Related disease | Ref |
|---|---|---|---|---|
| DRP1 | DRP1 regulates mitochondrial fission; excessive fission leads to fragmentation, altered mitochondrial function | Inhibition of DRP1 suppress PANoptosis by modulating apoptotic, pyroptotic, and necroptotic pathways | Glaucoma; Spleen injury; Ulcerative colitis; Doxorubicin-induced cardiotoxicity | [11], [16], [123], [124] |
| PGAM5 | PGAM5 regulates mitochondrial dynamics; its deficiency leads to increased mitochondrial fusion and impaired mitochondrial turnover, and elevated intracellular ROS levels | Increased PGAM5 in cytosol activates RIPK1, driving the assembly of the RIPK1-PANoptosome | Subarachnoid hemorrhage | [19] |
| VDAC1 | VDAC1 regulates mitochondrial oxidative stress by regulating metabolite flux and ROS dynamics across the outer membrane | Increased VDAC1 oligomerization disrupts mitochondrial permeability, leading to mitochondrial dysfunction, oxidative stress, and PANoptosis | Glaucoma | [8] |
| NRF2 | NRF2 reduces mitochondrial oxidative stress by activating antioxidant genes that neutralize ROS and restore redox balance | NRF2 knockout exacerbates PANoptosis by promoting apoptosis-dependent, pyroptosis-dependent, and necroptosis-dependent pathways | Cisplatin-induced kidney injury; Cisplatin-induced nephrotoxicity; Spleen injury; Colorectal cancer | [16], [125] |
| WTAP | WTAP decreases intracellular oxidative stress by maintaining the NRF2 expression in an m6A-dependent manner | WTAP depletion triggers m6A-dependent PANoptosis through NRF2 | Colorectal cancer | [126] |
| AIM2 | AIM2 mitigate oxidative stress by modulating autophagy and NRF2 pathway | AIM2 binds to ZBP1 and forms an AIM2 PANoptosome to drive PANoptosis | Acute liver injury; HSV1 infection | [6], [127], [128] |
| Bax/Bcl-2 | Bax/Bcl-2 regulates mitochondrial oxidative stress by controlling mitochondrial outer membrane permeabilization | Increased Bax promotes PANoptosis by inducing mitochondrial outer membrane permeabilization, triggering caspase activation; Bcl-2 counteracts this process | Spinal cord injury; Glaucoma | [5], [76], [89] |
| Lgals3 | Lgals3, also known as Galectin-3, involves in regulation of mitochondrial quality control by modulating Bax | Inhibition of Lgals3-Bax axis stabilizes mitochondrial quality and inhibits PANoptosis induction | Spinal cord injury | [5] |
| TLR2/4 | TLR2/4 activation enhances mitochondrial oxidative stress by recruiting TRAF6-ECSIT to mitochondria, boosting mitochondrial ROS production | Activation of TLR2/4 signaling mediates regulation of NLRC5 expression and ROS production to modulate PANoptosis | Hemolytic disease | [9], [129] |
Abbreviations: Drp1, dynamin-related protein 1; PGAM5, phosphoglycerate mutase family member 5; ROS, reactive oxygen species; RIPK1, receptor-interacting protein kinase 1; VDAC1, voltage-dependent anion channel 1; NRF2, nuclear factor E2-related factor 2; WTAP, Wilms' tumor 1-associated protein; AIM2, absent in melanoma 2; ZBP1, Z-DNA binding protein 1; TLR2/4, toll-like receptor 2/4; TRAF6, TNF receptor associated factor 6; ECSIT, evolutionarily conserved signaling intermediate in Toll pathways; NLRC5, NLR Family CARD Domain Containing 5.
Mitochondrial oxidative stress and apoptosis
Oxidative stress triggers apoptosis via mitochondria-dependent pathways [52], [53]. Caspases initiate apoptosis triggered by mitochondrial oxidative stress, which disrupts the mitochondrial membrane integrity, resulting in the cytochrome c release that binds with Apaf-1 to form the apoptosome complex. This complex facilitates the activation of caspase-9, which cleaves the precursor of caspase-3, converting it into active caspase-3 [52]. In parallel, mitochondrial oxidative stress can also trigger caspase-independent apoptosis via a mitochondrial factor AIF (Apoptosis-Inducing Factor). Upon oxidative stress, AIF mediates apoptosis by translocating to the nucleus, resulting in the DNA damage and fragmentation [53].
Mitochondrial oxidative stress and necroptosis
Necroptosis is an inflammatory regulated cell death characterized by plasma membrane rupture and cell swelling [54]. Mitochondrial oxidative stress promotes necroptosis through a series of complex molecular mechanisms. The accumulation of ROS activates receptor-interacting protein kinase 1 (RIPK1), which in turn activates RIPK3 [55]. Activated RIPK3 thereby induces the activation of the mixed lineage kinase domain-like protein (MLKL) and its oligomerization and translocation to the plasma membrane, forming lytic pores that lead to membrane rupture [56]. This process disrupts ionic gradients and induces necroptotic cell death through osmotic lysis [54]. This inflammatory reaction accelerates the spread of necroptosis and may contribute to systemic inflammatory response syndrome and other systemic pathological changes.
Mitochondrial oxidative stress and pyroptosis
Pyroptosis is an inflammatory cell death pathway mediated by the nod-like receptor protein 3 (NLRP3) inflammasome and caspase-1 cleavage [57]. This process induces gasdermin-D (GSDMD)-dependent plasma membrane pore formation, lytic cell rupture, release of pro-inflammatory cytokines, and activation of the innate immune response. ROS generated by mitochondria serve as a “second signal” to oxidize NLRP3 protein and damage the mitochondrial membrane, promoting the NLRP3 inflammasome activation and release of mtDNA [58]. Furthermore, ROS also disrupts the TXNIP-thioredoxin complex, releasing TXNIP to directly interact with NLRP3 and enhance its activation [59]. ROS and mtDNA act as damage-associated molecular patterns (DAMPs) to induce TXNIP-dependent NLRP3-apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization, enabling pro-caspase-1 self-cleavage and subsequent gasdermin-D (GSDMD) processing [58]. Active caspase-1 cleaves GSDMD, releasing its N-terminal pore-forming domain, which oligomerizes and inserts into the plasma membrane, generating lytic pores that facilitate IL-1β and IL-18 secretion, thereby executing pyroptosis [57]. In addition, lipid peroxidation occurs when ROS oxidize polyunsaturated fatty acids in cell membranes, generating active metabolites such as MDA and 4-HNE [3]. These products disrupt membrane structural integrity and enhance the ability of GSDMD-N to insert into the membrane, facilitating pore formation and accelerating the pyroptosis process [60].
Mitochondrial oxidative stress and PANoptosis
Oxidative stress participates in the PANoptosome formation and PANoptosis through multi-layered molecular mechanisms. During this process, Caspase-8, ASC, NLRP3, RIPK1 serve as key platforms for inflammasome assembly, bridging ROS sensing and PANoptosome formation [9].
Z-DNA binding protein 1 (ZBP1), a key regulator of PANoptosome, detects nucleic acid stress signals triggered by ROS [6]. Through its RHIM domain, ZBP1 interacts with RIPK3, thereby inducing MLKL phosphorylation and necroptosis execution. Additionally, ZBP1 can form a complex with Caspase-8 to directly integrate apoptosis and necroptosis signals, granting ZBP1-PANoptosome the versatility to regulate cell death across different cell types [61]. ZBP1-mediated PANoptosis is commonly observed in viral infections, radiation damage, and high ROS environments, highlighting its essential role in response to acute cellular injury [6], [61].
On the other hand, the NLRP3 inflammasome, as a ROS-responsive sensor, is activated through ROS-mediated potassium efflux, mtROS production, and the release of mtDNA [62]. Upon assembly of the NLRP3-PANoptosome, ASC functions as an adaptor to bind to and activate Caspase-1, leading to the GSDMD cleavage, thus initiating pyroptosis. In parallel, activated Caspase-1 cooperates with Caspase-8 to activate Caspase-3/7, thereby initiating apoptosis and achieving crosstalk between pyroptosis and apoptotic signaling pathways [63]. NLRP12, a recently identified regulator of PANoptosis, can be activated by oxidative stress. It has been shown that stimulation with heme plus PAMPs increases ROS production and promotes the interaction of NLRP12 with ASC and Caspase-8 to form the NLRP12-PANoptosome [7].
Among these PANoptosome platforms, Caspase-8 is considered a central “hub” signaling executor in PANoptosis [6], [64]. It activates downstream Caspase-3/7 to trigger classical apoptosis, regulates necroptosis through cooperation with RIPK1/RIPK3. and indirectly modulates pyroptosis through crosstalk with Caspase-1 [57]. RIPK1/3 and MLKL are also indispensable in the PANoptosis pathway [65]. RIPK1 regulates the FADD-Caspase interaction, thereby modulating the PANoptosome and integrating different death signals [66]. Recently, Sundaram et al. indicated that excessive ROS promote the assembly of a NLRC5-PANoptosome consisted by NLRC5, ASC, Caspase-8, NLRP3, and RIPK3, leading to PANoptosis-mediated cell death [9].
Overall, oxidative stress not only drives PANoptosis by activating PANoptosome sensors and executioner proteins, but also serves as a “bridge” connecting various death signaling pathways, enabling their crosstalk and positive feedback amplification.
Roles of mitochondrial oxidative stress-mediated PANoptosis in neurological diseases
Mitochondrial oxidative stress is a major contributor to the induction of PANoptosis in neurological diseases. By disrupting neuronal homeostasis, amplifying neuroinflammation, and triggering cell death, mitochondrial oxidative stress-mediated PANoptosis drives the pathogenesis of neurological disorders.
Alzheimer’s disease
The integrated PANoptosis pathways − pyroptosis, apoptosis, and necroptosis − play important roles in AD pathogenesis, with oxidative stress serving as a key driver [10], [61]. Oxidative stress contributes to Aβ42-induced neuronal death by mediating both apoptotic and necroptotic pathways, thereby exacerbating AD pathology [67]. Specifically, Aβ42 increases intracellular ROS levels, which act as upstream signals to induce apoptosis [67]. In addition, excessive ROS promotes phosphorylation of RIPK3 to trigger necroptotic pathway. Similarly, Zhou et al. reported that in SH-SY5Y cells treated with Aβ42, excessive ROS accumulation triggers NLRP3 inflammasome activation, which triggers pyroptotic pathway [68]. These parallel pathways collectively damage neurons and exacerbate AD pathology.
A recent bioinformatic analysis identified 24 differentially expressed PANoptosis-associated genes in AD patients, suggesting an involvement of PANoptosis in AD progression [10]. Notably, among these genes, several key regulators of mitochondrial oxidative stress-including TNF Receptor Superfamily Member 1A (TNFRSF1A), Transforming Growth Factor Beta 2 (TGFB2), and Platelet-Derived Growth Factor Receptor Beta (PDGFRB)-were significantly upregulated in AD. This suggests a mechanistic link between mitochondrial oxidative stress and PANoptosis activation in AD pathogenesis. By integrating multi-omics approaches, this study revealed the potential associations between PANoptosis and AD pathogenesis, providing theoretical support and potential targets for AD subtyping, risk prediction, and targeted therapy [10]. Collectively, the convergence of mitochondrial oxidative stress and the integrated PANoptosis pathway (encompassing pyroptosis, apoptosis, and necroptosis) serves as a key pathogenic axis in AD.
Parkinson’s disease
In the context of PD, mitochondrial dysfunction and oxidative stress trigger dopaminergic neurodegeneration through multiple cell death pathways. In a classical PD model induce by 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine (MPTP), the mitochondrial complex I deficiency increase the production of ROS, which promote the cytochrome c release with the upregulation and mitochondrial translocation of Bax, leading the apoptotic dopaminergic neurodegeneration [69]. Mutations in the OPA1, a gene found in inherited form of PD, induces dysfunctions in mitochondrial dynamics and oxidative stress that promotes the assembly of necrosome and activation of necroptotic pathway, driving the dopaminergic cell loss [4]. Activation of the NLRP3 inflammasome-mediated pyroptosis also contributes to the dopaminergic neurodegeneration in PD. Carvacrol, a natural extract holding antioxidant and anti-inflammatory properties, has been administrated to promote the antioxidant defenses through the activation of the Nrf2 and inhibit the inflammasome-mediated pyroptosis in PD mouse models [70].
Emerging evidence indicates that PANoptosis serves as a key pathological driver in PD. In a PD depression model induced by 6-hydroxydopamine (6-OHDA), microglial activation induced by reduction of dopamine D2 receptor (DRD2) improves the expression of ZBP1, which triggers PANoptosis and subsequent neuron loss in medial prefrontal cortex (mPFC) [71]. ZBP1 knockdown in mPFC neurons attenuates PANoptosome assembly, mitigates neuronal damage, and improves depressive-like phenotypes. This study reveals that microglial DRD2 downregulation promotes ZBP1 activation, leading to PANoptosis-mediated neurodegeneration and disrupted dopaminergic signaling in PD. Thus, PANoptosis drives dopaminergic neurodegeneration in PD by integrating multiple mitochondrial oxidative stress-induced death pathways. Its activation through specific triggers like DRD2/ZBP1 axis positions it as a critical link between neuroinflammation, dopaminergic signaling disruption, and neuronal loss, offering a novel target for intervention.
Spinal cord injury
Spinal cord injury is a devastating neurological disorder marked by extensive neuronal death, microglial activation, and profound motor impairment [72]. Emerging evidence indicates that spinal cord injury triggers PANoptosis through the galectin-3 (Lgals3)-Bax signaling axis [5]. Following spinal cord injury, Lgals3 is upregulated and collaborates with Bax to promote mitochondrial fragmentation, increases the expression of RIPK1, and partially activates apoptotic caspase-3. Notably, zinc ions, by targeting the Lgals3-Bax axis, can alleviate oxidative stress, preserve mitochondrial integrity, and significantly reduce PANoptosis in spinal cord injury mice [5]. This protective effect of zinc in mitigating oxidative stress and maintaining mitochondrial function is consistent with findings from previous study [73].
Other studies have also confirmed that PANoptosis is widely present in spinal cord injury. Y-box binding protein 1 (YBX1), a key member of the RNA-binding protein family, functions to modulate gene expression, RNA splicing, and mRNA degradation [74]. Lou et al. demonstrated that YBX1 stabilizes the mRNA of ZBP1, thereby enhancing its expression in spinal cord injury mice [72]. This upregulation triggers PANoptosis through activation of caspase-1/3 and RIPK3, ultimately driving neuronal cell death. Moreover, it was found that the tripartite motif-containing 56 (TRIM56), an E3 ubiquitin ligase, suppresses ZBP1 expression and PANoptosis activation by promoting the ubiquitin-mediated degradation of YBX1 [72].
Moreover, PANoptosis is induced in spinal cord ischemia–reperfusion injury [75], [76]. Xie et al. found that melatonin exerted neuroprotective effects by reducing neuronal apoptosis, necroptosis, and pyroptosis-demonstrating anti-PANoptosis activity in rat models of spinal cord ischemia–reperfusion injury [75]. Additionally, treatment with the GYY4137, a slow-releasing hydrogen sulfide (H2S) donor, downregulates the apoptotic markers (cleaved caspase-3 and Bax), necroptotic markers (p-RIPK3 and p-MLKL), and pyroptotic markers (NLRP3 and cleaved GSDMD) in rats with spinal cord ischemia‒reperfusion injury [76]. Both H2S and melatonin can also act as protective agents through their anti- oxidative properties, counteracting ischemia- and hypoxia-induced neuronal injury [77]. Interestingly, a recent study reveals that PANoptosis and ferroptosis co-occur and synergistically exacerbate myocardial ischemia–reperfusion injury in mouse models [78]. Mitochondrial oxidative stress induced by downregulation of the α7 nicotinic acetylcholine receptor (α7nAChR) serves as a critical link between these two cell death pathways. However, the role and interplay of these pathways in spinal cord ischemia–reperfusion injury and other neurological diseases remain largely unexplored and represent an important direction for future research.
Subarachnoid hemorrhage
Subarachnoid hemorrhage is an acute cerebrovascular disease caused by the entry of blood into the subarachnoid space of the brain [79]. The PANoptotic pathway activated after subarachnoid hemorrhage involves PGAM5 overexpression, which regulates the mitochondrial dynamics [80]. Under physiological conditions, PGAM5 is embedded in the mitochondrial membrane to exert its function. In an endovascular perforation-induced subarachnoid hemorrhage model, PGAM5 failed to localize to mitochondria and instead abnormally accumulated in the cytoplasm [19]. The cytosolic PGAM5 binds to and activates RIPK1 at the Ser166 site, thereby promoting the PANoptosome assembly. Silencing PGAM5 using siRNA effectively reduced its cytosolic levels, suppressed RIPK1 activation and PANoptosome formation, significantly alleviating PANoptosis and improving neurological outcomes in subarachnoid hemorrhage rats [19].
Beyond its role in mitochondrial targeting, PGAM5 is also a regulator of oxidative stress. Its deficiency disrupts mitochondrial dynamics and elevates intracellular ROS levels, exacerbating oxidative stress in retinal pigment epithelial senescence in vitro and in vivo [80]. Additionally, PGAM5 can interact with DRP1 and promote its phosphorylation at Ser622 and Ser643, leading to excessive mitochondrial fission and dysfunction in mice following traumatic brain injury [81]. PGAM5 also participates in regulating mitophagy, partially through the PINK1/Parkin pathway, to remove damaged mitochondria. Thus, the oxidative stress-PGAM5-PANoptosis axis may play a central role in secondary injury of subarachnoid hemorrhage and represents a promising target for future therapeutic interventions. Taken together, PGAM5 emerges as a critical regulator in subarachnoid hemorrhage, bridging impaired mitochondrial quality control, oxidative stress, and PANoptotic cell death. Targeting this nexus offers a promising therapeutic target for this disease.
Ischemic stroke
Ischemic stroke, an acute cerebrovascular disorder caused by abrupt cessation of blood flow to brain regions, leads to hypoxic-ischemic injury that induces neuronal damage and cell death [82]. Oxidative stress and PANoptosis serving as key drivers of neuronal injury during ischemic and reperfusion phases [83]. Cheng et al. demonstrated that caspase-8-mediated PANoptosis, involving all three regulated cell death pathways, contributes to ischemic stroke pathology in rat model of cerebral infarction [84]. Additionally, the repeated transcranial magnetic stimulation (rTMS) combined with mesenchymal stem cell transplantation can effectively reduce PANoptosis, alleviate neuronal injury following ischemic stroke. rTMS is a non-invasive neuromodulation technique that improves clinical outcomes in ischemic stroke patients [82].
Furthermore, several interventions have been reported to suppress PANoptosis following ischemic stroke. Esculentoside H, a bioactive compound derived Phytolacca esculenta, exerts neuroprotective effects against ischemia–reperfusion injury by upregulating transducin-like enhancer of split-1 (TLE1) and activating the PI3K/AKT signaling pathway in rat model of middle cerebral artery occlusion [83]. The PI3K/AKT pathway is closely involved in the regulation of antioxidant capacity by activating downstream transcription factors and inducing the expression of SOD and CAT, thereby reducing ROS-induced damage [85]. In addition, Curcumin-primed olfactory mucosa-derived mesenchymal stem cells demonstrate dual therapeutic effects in cerebral ischemia/reperfusion injury, exhibiting both antioxidant activity and PANoptosis inhibition [86]. Moreover, Calycosin, a natural product extracted from Astragalus membranaceus, mitigates ischemic stroke by suppressing PANoptosis through modulation of key regulators (NLRP3, GSDMD, and MLKL) [87]. Therefore, the antioxidant properties of Esculentoside H, Curcumin, and Calycosin appear to be closely related to their neuroprotective effects against PANoptosis in ischemic stroke.
In summary, mitochondrial oxidative stress-mediated PANoptosis is a central driver of neuronal injury in ischemic stroke. Targeting this axis, either through neuroprotective agents (e.g., Esculentoside H, Curcumin, Calycosin) that mitigate upstream oxidative stress, or via combined approaches like rTMS and stem cell therapy that inhibit PANoptosis execution, represents a promising and multifaceted therapeutic strategy to improve stroke outcomes and other neurological diseases.
Glaucoma
Glaucoma, the world's leading cause of blindness, is a progressive neurodegenerative disorder characterized by visual field defects and optic nerve damage [11]. Elevated intraocular pressure is a primary pathogenic factor in glaucoma, driving disease progression through retinal oxidative stress, neuroinflammatory responses, and ischemia–reperfusion injury mechanisms. Recent studies have revealed that PANoptosis contributes to glaucomatous neurodegeneration, serving as an important executioner of retinal ganglion cell death. [88], [89].
Mitochondrial oxidative stress aggravates PANoptosis in glaucoma through complex mechanisms. In a mouse model of glaucoma, increased phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) induces the Drp1phosphorylation, which promotes excessive mitochondrial fission and ROS production [90], [91]. Excessive ROS further aggravates mitochondrial damage and ultimately induces retinal ganglion cell PANoptosis [90]. Inhibition of the ERK1/2-Drp1-ROS axis effectively suppresses the expression of key PANoptosis proteins and significantly alleviates retinal ganglion cell death, indicating that oxidative stress-induced PANoptosis is a central pathogenic mechanism in mouse model of glaucoma [11].
Furthermore, voltage-dependent anion channel 1 (VDAC1) oligomerization-mediated mitochondrial dysfunction is linked to PANoptosis in retinal ischemia–reperfusion injury [8], [92]. Increased VDAC1 oligomerization disrupts mitochondrial permeability, resulting in mitochondrial dysfunction and PANoptosis. Inhibition of VDAC1 oligomerization alleviates mitochondrial dysfunction and oxidative stress, thereby suppressing PANoptosis in rat retinas following ischemia–reperfusion injury. Moreover, it is indicated that mitochondria-derived ROS facilitates VDAC1-mediated regulation of PANoptosis through regulating PANoptosome assembly and PANoptosis induction [8]. Therefore, mitochondrial oxidative stress is a key driver of glaucomatous neurodegeneration, triggering PANoptosis via two key mechanisms: promoting excessive mitochondrial fission through the ERK1/2-Drp1 axis and disrupting mitochondrial integrity via VDAC1 oligomerization. These findings highlight promising avenues for preserving vision in glaucoma.
Traumatic brain injury
Traumatic brain injury triggers oxidative stress that promotes multiple forms of regulated cell death, impairing neuronal survival and functional recovery. Deubiquitinating enzyme PSMD14 is markedly upregulated in neurons post-traumatic brain injury, and its deficiency results in excessive ROS production, redox homeostasis disruption, and subsequent activation of PANoptosis in mouse model of traumatic brain injury [22]. The ROS scavenger N-acetylcysteine effectively alleviates these effects, indicating that ROS serves as a critical mediator of PANoptosis activation following traumatic brain injury [22], [65]. Further mechanistic investigations reveal that PSMD14 maintains mitochondrial homeostasis by sustaining PRKN-mediated mitophagy, thereby promoting damaged mitochondria clearance, limiting generation of ROS, and suppressing PANoptosis [22]. Thus, these findings identify oxidative stress-driven PANoptosis as a key driver of pathology in traumatic brain injury.
Taken together, mitochondrial oxidative stress is critical to activation of PANoptosis and multiple cell death signaling, driving the pathogenesis of these disorders. Understanding how oxidative stress regulates PANoptosis is essential for revealing the shared pathological mechanisms and identifying potential therapeutic targets for neurological diseases.
Targeting mitochondrial oxidative stress-mediated PANoptosis holds promise for suppressing neuroinflammation and neurodegeneration
Building on the established link between mitochondrial oxidative stress and PANoptosis in driving disease pathogenesis, this section transitions into therapeutic interventions. Targeting the axis of mitochondrial oxidative stress-mediated PANoptosis emerges as a promising strategy to suppress inflammatory response and neuron death (Fig. 4). Here, we discuss current and emerging therapeutic approaches targeting PANoptosis signaling pathways, with emphasis on the mitochondrial-targeted antioxidants, regulators of mitochondrial dysfunction, and specific inhibitors of key proteins in apoptosis, necroptosis, and pyroptosis (Table 3).
Fig. 4.

Targeting mitochondrial ROS-mediated PANoptosis to suppress neuroinflammation and neurodegeneration. Dysfunctional mitochondrial respiration and dynamics drive pathological ROS overproduction, which critically stimulates PANoptosome assembly. This complex initiates PANoptosis by activating executioner molecules—including CASP3/7 (apoptosis), GSDMD (pyroptosis), and phosphorylated MLKL (necroptosis). PANoptosis promotes neuroinflammatory responses and contributes to progressive neurodegeneration. Multiple pharmacological agents that reduce mitochondrial ROS or inhibit PANoptotic components are shown to interrupt this pathogenic cascade. Mito-TEMPO, N-acetylcysteine, and melatonin attenuate ROS generation. Mdivi-1 normalizes mitochondrial dynamics by inhibiting Drp1-mediated fission. MCC950 suppresses NLRP3 inflammasome activation, Z-VAD-FMK blocks caspase activity, and GSK’872 inhibits RIPK3, thereby disrupting PANoptosome formation and execution. Together, these interventions mitigate PANoptosis and its downstream consequences, providing therapeutic potential for treating neurological diseases. Created with BioRender.com.
Table 3.
Potential therapeutic approaches targeting PANoptosis in neurological diseases.
| Strategy | Agent | Mechanism | Benefit | Clinical Status | Ref |
|---|---|---|---|---|---|
| ROS/mtROS scavenging | N-acetylcysteine | Reducing ROS levels | N-acetylcysteine alleviates excessive accumulation of ROS, disruption of redox homeostasis, and subsequent activation of PANoptosis in neurons following traumatic brain injury | FDA-approved uses | [22] |
| Melatonin | Reducing ROS levels | Melatonin reduces oxidative stress and suppresses the activation of PANoptosome complexes that drive PANoptosis signaling following spinal cord injury | FDA-approved uses | [75] | |
| Mito-TEMPO | Reducing mtROS levels | Mito-TEMPO reduces mitochondrial redox levels, inhibits the MFN2 function, and reduces CdCl2-induced PANoptosis and neurotoxicity | Preclinical Evidence | [21] | |
| Mitochondrial dysfunction regulation | Mdivi-1 | Inhibiting the GTPase activity of DRP1 | Mdivi-1 improves mitochondrial function and downregulates apoptotic markers, pyroptosis-related proteins, and necroptosis markers, comprehensively inhibiting the activation of PANoptosis following glaucoma | Preclinical Evidence | [11] |
| VBIT-12 | Inhibiting the oligomerization of VDAC1 | VBIT-12 prevents VDAC1 oligomerization-mediated mitochondrial membrane permeabilization, alleviates mitochondrial oxidative stress and activation of PANoptosis in retinal ischemia–reperfusion injury | Preclinical Evidence | [8] | |
| Caspases inhibition | Q-VD-OPh | Inhibiting caspases broadly | Q-VD-OPh blocks α-synuclein-induced mitochondrial damage and neuron loss in Parkinson’s disease | Preclinical Evidence | [57] |
| Z-IETD-FMK | Inhibiting caspase-8 | Z-IETD-FMK protects retinal ganglion cells against apoptosis and glia-driven inflammatory injury in experimental glaucoma | Preclinical Evidence | [107] | |
| YVAD-CMK | Inhibiting caspase-1 | YVAD-CMK inhibits α-synuclein-induced caspase activation and enhances the viability of α-synuclein-overexpressing dopaminergic neurons | Preclinical Evidence | [57] | |
| ABT-199 (Venetoclax) | Inhibiting BCL-2 | ABT-199 significantly decreases the population of hyperphosphorylated tau-positive neurons in Alzheimer's disease models | FDA-approved uses | [108] | |
| RIPK1/3/MLKL inhibition | Nec-1, Nec-1 s | Inhibiting RIPK1 | Nec-1 and Nec-1 s inhibit microglial activation and provide neuroprotective effects by inhibiting the RIPK1 phosphorylation in Parkinson’s disease models | Preclinical Evidence | [109] |
| GSK’872 | Inhibiting RIPK3 | GSK’872 alleviates loss of mitochondrial integrity and excessive accumulation of ROS, ameliorating the spinal cord edema following spinal cord injury | Preclinical Evidence | [111] | |
| Necrosulfonamide | Inhibiting MLKL | Necrosulfonamide improves antioxidative capacity and inhibits MLKL-dependent necroptosis, ameliorating neurological impairment following spinal cord injury | Preclinical Evidence | [113] | |
| NLRP3 inflammasome inhibition | MCC950 | Inhibiting NLRP3 | MCC950 reduces the inflammasome activation, accumulation of α-synuclein aggregates, and dopaminergic degeneration in Parkinson’s disease models | Preclinical Evidence | [115] |
| CY-09 | Inhibiting NLRP3 | CY-09 suppresses neuroinflammation through NLRP3 inflammasome pathway following experimental stroke | Preclinical Evidence | [119] | |
| Prussian blue nanozyme | Inhibiting NLRP3 | Prussian blue nanozyme reduces the damage of mitochondrial membrane potential and pyroptosis by scavenging ROS and activation of NLRP3 inflammasomes in Parkinson’s disease models | Preclinical Evidence | [120] |
Abbreviations: ROS, reactive oxygen species; MFN2, Mitofusin 2; DRP1, dynamin-related protein 1; VDAC1, voltage-dependent anion channel 1; RIPK1, receptor-interacting protein kinase 1; MLKL, mixed lineage kinase domain-like protein; NLRP3, nod like receptor protein
N-acetylcysteine
N-acetylcysteine (NAC), an FDA-approved antioxidant, maintains cellular redox homeostasis by replenishing GSH and directly scavenging ROS [93]. NAC exhibits protective effects in various oxidative stress-related diseases, especially those affecting the nervous system [65], [93]. Notably, NAC significantly suppresses PANoptosis in NS20Y neuronal cells by inhibiting oxidative stress. It scavenges intracellular ROS and inhibits the activation of TLR4/NF-κB pathway, which downregulates the activation of ZBP-1, significantly reducing SiO2-induced PANoptosis [94].
NAC exerts a synergistic inhibitory effect on PANoptosis. A Recent study indicates that in a microglia-neuron co-culture system, NAC exhibits significant neuroprotective effects [95]. When microglia phagocytose zinc oxide nanoparticles, NOX2 is activated, generating large amounts of ROS and thereby triggering PANoptosis [95]. In addition, NAC could effectively eliminate ROS and block the P2X7R/NLRP1/caspase-1 axis, thereby reducing pyroptotic neuronal injury in high glucose-induced HT22 cells [96]. Furthermore, NAC mitigates mitochondrial oxidative stress and restores mitochondrial redox balance. It inhibits S-glutathionylation of mitofusin 2, preserves the structural stability of mitochondria-associated membranes, and blocks activation of necroptotic pathway, thereby alleviating CdCl2-induced neurotoxicity in vivo and in vitro [21].
Taken together, these findings demonstrate that NAC, by suppressing oxidative stress and modulating multiple cell death pathways, holds therapeutic potential in addressing PANoptosis and complex neuronal injuries.
Mito-TEMPO
Mito-TEMPO is a mitochondria-directed antioxidant synthesized by conjugating the stable free radical TEMPO (2,2,6,6-tetramethylpiperidine-1-oxyl) to a lipophilic triphenylphosphonium cation [11]. This modification enables Mito-TEMPO to specifically accumulate in mitochondria and efficiently scavenge mtROS. In the model of CdCl2-induced neurotoxicity, Mito-TEMPO reduces mitochondrial redox levels, inhibits the S-glutathionylation of MFN2, and suppresses PANoptosis and neurotoxicity [21]. In mouse model of glaucoma, it inhibits PANoptosis in retinal ganglion cells induced by high intraocular pressure through Drp1-mediated mitochondrial dysfunction [11]. Mito-TEMPO has also been found to inhibit PANoptosis in PD. In the mouse model of PD induced by rotenone, Mito-TEMPO inhibits mtROS production, reduces NOX4 activity, and prevents mitochondrial dysfunction induced by short-chain enoyl-CoA hydratase 1 (ECHS1) silencing, significantly suppressing cell apoptosis [97].
Additionally, Mito-TEMPO has shown inhibitory effects on pyroptosis and necroptosis in various disease models. In models of neuroinflammation related to methamphetamine, Mito-TEMPO reduces methamphetamine-induced microglia activation, ROS production, and subsequent NLRP3 inflammasome activation, thereby inhibiting pyroptosis in rat microglial cultures [98]. In mice with Pseudomonas aeruginosa infection, Mito-TEMPO reduces ROS release associated with mitochondrial membrane potential changes and inhibits MLKL-dependent necroptosis signaling, ultimately suppressing necroptosis [99]. These findings suggest that Mito-TEMPO is a versatile modulator of multiple cell death signaling, such as apoptosis, pyroptosis, necroptosis, and their convergence in PANoptosis, highlighting its therapeutic potential for neurological disorders.
Melatonin
Melatonin is a circadian-regulated indoleamine hormone, involved in sleep regulation, antioxidation, and immune modulation. In rat model of spinal cord ischemia–reperfusion injury, it reduces oxidative stress and suppresses the activation of PANoptosome complexes (ZBP1 and NLRP3) that drive PANoptosis signaling [75]. Additionally, in acute ocular hypertension-injured mouse retinas, melatonin reduces retinal ganglion cell loss, decreases microglial activation and IL-1β release, preserves retinal structure, and improves visual function [89].
In mouse model of cerebellar injury induced by atrazine, melatonin mitigates mitochondrial dysfunction by preventing the decline in membrane potential and reducing histopathological damage [100]. Additionally, atrazine exposure triggers mitochondrial damage, resulting in mtDNA leakage into the cytoplasm, while melatonin attenuates these effects by activating the cGAS-STING axis, thereby attenuating pyroptosis and inflammation. In chemotherapy-induced brain dysfunction caused by doxorubicin in male rats, treatment with melatonin alleviated oxidative stress, restored glial morphology and function, and reduced brain inflammation (lowered pro-inflammatory markers) [101]. Additionally, melatonin decreased apoptosis and necroptosis, while enhancing hippocampal plasticity and neurogenesis, ultimately improving cognitive performance.
Mdivi-1
Mdivi-1, a mitochondrial division inhibitor, preserves mitochondrial homeostasis by suppressing Drp1 GTPase activity [79]. In the mouse model of glaucoma, Mdivi-1 enhances mitochondrial function and reduces excessive ROS, leading to the significant downregulation of apoptotic (cleaved-caspase3), pyroptotic (NLRP3/caspase1/GSDMD), and necroptotic markers (p-RIPK1/p-RIPK3/p-MLKL) [11]. By targeting these pathways, it effectively suppresses PANoptosis activation and prevents morphological damage and loss of ganglion cells.
For sepsis-associated encephalopathy, Mdivi-1 can inhibit mitochondrial fragmentation in microglia and attenuate oxidative stress and neuroinflammation by modulating the Kelch-like ECH-associated protein 1 (KEAP1)/NRF2/HO-1 pathway following sepsis in mice [102]. Meanwhile, Mdivi-1 increases the level of p62, promotes autophagosome formation, reduces microglial pyroptosis, and ultimately improves cognitive dysfunction in sepsis-associated encephalopathy patients. Additionally, as a Drp1 inhibitor, Mdivi-1 can effectively reverse abnormal mitochondrial fission, decreases ROS production, and suppresses NLRP3 inflammasome activation, thereby blocking pyroptosis and protecting against neuronal injury in a rat model of neuroinflammation induced by high-fat diet [26].
In a rat endovascular perforation model of subarachnoid hemorrhage, Mdivi-1 can reverse abnormal mitochondrial morphology and Drp1 translocation, reduce ROS levels, reduce pro-apoptotic protein expression, and promote the Bcl-2 expression, ultimately inhibiting neuronal apoptosis and improving neurological function [79]. Transient global cerebral ischemia induces neuronal death through RIPK3-mediated necroptosis and CaMKIIα activation, leading to Drp1 Ser637 dephosphorylation and mitochondrial fission in adult rats [103]. Mdivi-1 can prevent Drp1 dephosphorylation and translocation, and inhibit mitochondrial fission, blocking mitochondrial damage-related signaling pathways and reducing neuronal injury. In studies on the neurotoxicity of silver nanoparticles (AgNPs), it was found that Low-dose AgNPs increase ROS, impair mitochondrial function, and upregulate Drp1, leading to excessive fission and apoptosis in hippocampal HT22 cells [18]. Mdivi-1 also demonstrates efficacy against silver nanoparticle (AgNP) neurotoxicity, where it counteracts AgNP-induced Drp1 upregulation, mitochondrial fragmentation, and apoptosis.
These findings collectively highlight Mdivi-1′s ability to mitigate diverse neuropathological processes through its fundamental action on mitochondrial dynamics, highlighting it as a promising therapeutic candidate for multiple neurological disorders.
VBIT-12
VBIT-12 is a small-molecule compound that selectively binds to VDAC1 monomers to prevent their oligomerization, thereby inhibiting mitochondrial membrane permeabilization [92]. In a rat model of retinal ischemia–reperfusion injury, VBIT-12-mediated inhibition of VDAC1 oligomerization reduces mitochondrial dysfunction and oxidative stress while suppressing PANoptosome assembly and PANoptosis induction [8]. VBIT-12 also alleviates ROS production and cytosolic Ca2+ overload, rescues mutant SOD1-induced neuronal death, and improves muscle endurance in mice and rats models of ALS [104]. Furthermore, VBIT-12 preserves the ultrastructure of mitochondria-associated endoplasmic reticulum membranes and extends survival in rat hemorrhagic shock models [105]. By targeting VDAC1 oligomerization, VBIT-12 emerges as a versatile therapeutic candidate for multiple pathological conditions involving mitochondrial dysfunction, aberrant cell death pathways, and endoplasmic reticulum-mitochondria dysregulation.
Caspases inhibitors
Caspases family play multifaceted roles in regulating cell death [57]. Caspase-8 drives PANoptosis by bridging apoptotic, pyroptotic, and necroptotic pathways through its scaffolding and proteolytic functions [6]. The Q-VD-OPh, a pan-caspase inhibitor, has been used in a rat PD model to block α-synuclein-induced mitochondrial damage and neuron loss [106]. In rat model of glaucoma, Z-IETD-FMK, a caspase-8 inhibitor, protects retinal ganglion cells against apoptosis and glia-driven inflammatory injury [107]. A specific caspase-1 inhibitor, YVAD-CMK, was also able to mitigate α-synuclein-mediated neurodegeneration in human dopaminergic neurons [106]. The Bcl-2 regulates apoptosis through modulating mitochondrial outer membrane permeabilization [91]. ABT-199 (venetoclax), a selective BCL-2 inhibitor, reduces Tau pathology in a mouse model of Alzheimer’s disease expressing human hyperphosphorylated tau [108]. These studies demonstrate neuroprotective potential of caspase inhibitors across multiple neurodegenerative models, but their pleiotropic effects indicate the need for more selective and context-specific targeting strategies.
Inhibitors of necroptotic pathway
The RIPK1/3 and MLKL are important regulators of necroptosis in neurological diseases [54]. The RIPK1 inhibitors necrostatin-1 (Nec-1) and its stable variant (Nec-1 s) suppress microglial activation and exert neuroprotection by blocking RIPK1 phosphorylation in lipopolysaccharide-injected mice and MPTP-induced PD mouse models [109]. Nec-1 also improves mitochondrial function and reduces hyperphosphorylated Tau and necroptosis in the brain of prediabetic rats [110]. A RIPK3 inhibitor, GSK’872, ameliorates spinal cord injury by preserving mitochondrial integrity, reducing ROS levels, and ameliorating spinal cord edema [111]. It also protects against diabetic retinal neurodegeneration through inhibition of RIPK3 and necroptosis in mouse model of spinal cord injury [112]. Recent studies have identified MLKL inhibitor, necrosulfonamide, which can enhance antioxidative capacity and block MLKL-dependent necroptosis, thereby improving outcomes in spinal cord injury mice [113]. In addition, MLKL inhibition by necrosulfonamide reduces neuroinflammation and cell damage in mouse PD model induced by MPTP [114]. Taken together, targeting the necroptotic signaling pathway demonstrates therapeutic promise in neurological diseases by mitigating mitochondrial dysfunction, necroptosis, and neuroinflammation.
Inhibitors of pyroptotic pathway
Aberrant NLRP3 inflammasome activation drives neuroinflammation and neuronal death. The NLRP3 inhibitor MCC950 exhibits therapeutic potential in multiple rodent PD models PD models by attenuating inflammasome activation, α-synuclein aggregation, and dopaminergic degeneration [115]. Additionally, inhibition of NLRP3 inflammasome by MCC950 enhances PINK1/Parkin-mediated autophagy, promoting mitochondrial turnover and suppressing lipopolysaccharide-induced neuroinflammation, thereby protecting dopaminergic neurons and inhibiting microglial activation upon lipopolysaccharide-induced neuroinflammatory injury in mice [116]. Systematic administration of MCC950 also can suppress the production of ROS and IL-1β, exerting offering protection in the striatum of R6/2 mice (a transgenic HD mouse model). [117]. Furthermore, MCC950 improves perioperative neurocognitive disorders by inhibiting the PI3K/AKT pathway and mitochondrial dysfunction-induced cognitive deficits in aged mice [118]. The other inhibitor of NLRP3, CY-09, also shows neuroprotective effects against neuroinflammation and neuronal pyroptosis following experimental stroke in mice [119]. Notably, a nanozyme, Prussian blue nanozyme (PBzyme), has been indicated as a potential pyroptosis inhibitor that alleviates neuron death. PBzyme can preserve mitochondrial membrane potential and block NLRP3-mediated pyroptosis in MPTP-induced PD mouse model [120]. These findings collectively highlight the therapeutic potential of NLRP3 inflammasome inhibitors in mitigating neuroinflammation and neurodegeneration across multiple neurological disorders, offering promising avenues for future clinical development.
Conclusions and future perspectives
The interplay between mitochondrial oxidative stress and PANoptosis is important to neurological diseases, presenting both opportunities and challenges for therapeutic development [5], [16]. The identification of novel therapeutic targets will require future research to focus on elucidating PANoptosis mechanisms in other neurological diseases, such as ALS, multiple sclerosis, and Huntington’s disease, with special attention to electron transport chain dysfunction and impaired mitochondrial dynamics [11]. Developing selective inhibitors that can precisely modulate cell death pathways without disrupting normal cellular functions will also be critical.
While targeting PANoptotic pathways offers promise, key obstacles remain, including the complexity of overlapping cell death mechanisms and disease heterogeneity across different neurological conditions. Beyond these hurdles, current approaches, such as mitochondrial antioxidants and caspase inhibitors, may face delivery challenges. The blood–brain barrier is highly selective, preventing over 98% of potential small molecules from reaching their cellular targets in the brain [121]. Additionally, achieving targeted delivery to specific cell types (e.g., neurons, activated microglia) or even to intracellular organelles such as mitochondria is crucial for maximizing efficacy and minimizing off-target effects. Advances in nanomedicine and gene therapy hold promise for overcoming these limitations enabling targeted interventions for PANoptosis. Engineered nanocarriers can be designed to enhance blood–brain barrier penetration via surface modifications with specific ligands (e.g., transferrin or angiopep-2). These carriers can also be functionalized with targeting moieties like antibodies or aptamers to achieve cell- or organelle-specific delivery [122].
Furthermore, the successful translation of PANoptosis-targeted therapies will depend on integrating precision medicine approaches, such as biomarker identification and omics technologies, to enable personalized treatments that address both shared and disease-specific aspects of neurodegeneration [10]. The discovery and validation of specific biomarkers serve as the cornerstone. This involves detecting signatures of PANoptosis activation (e.g., unique combinations of circulating proteins, metabolites, or expression levels of PANoptosome components) and associated mitochondrial oxidative stress (e.g., levels of oxidized lipids and mtDNA fragments). Moreover, multi-omics technologies-integrating genomics, transcriptomics, proteomics, and metabolomics-will enable the categorization of patients into distinct subgroups based on their dominant pathological drivers, thereby guiding interventions that target the unique molecular pathology of each patient’s condition.
Another key area for exploration is the relationship between PANoptosis and neuroinflammation, particularly the roles of microglia and astrocytes in disease progression [95]. Understanding these interactions could lead to therapies that simultaneously target oxidative stress, cell death, and inflammation. Targeting upstream PANoptosis sensors (e.g., ZBP1 and NLRC5) alongside ROS-responsive components of the PANoptosome (e.g., RIPK1 and NLRP3) may exert combined neuroprotective effects by simultaneously inhibiting multiple regulated cell death pathways. Furthermore, developing integrated formulations that combine agents against mitochondrial oxidative stress (e.g., NAC and Mito-TEMPO) with those targeting the PANoptosome complex (e.g., MCC950 and Nec-1 s) based on disease-specific PANoptosis signatures, could break the vicious cycle of mitochondrial dysfunction and cell death. These combination therapies that address multiple pathological processes involved in the PANoptotic pathways may offer a more effective approach given the complexity of neurological diseases.
In summary, the interplay between mitochondrial oxidative stress and PANoptosis critically contributes to neurological disease pathogenesis by driving neuronal dysfunction and degeneration. Excessive ROS generation disrupts mitochondrial integrity, activates inflammatory cascades, and triggers the integrated cell death response involving apoptosis, necroptosis, and pyroptosis. Emerging therapeutic approaches, such as mitochondrial antioxidants, mitochondrial dysfunction targeting drugs, and cell death inhibitors, demonstrate significant potential for neuroprotection in neurological disease.
Compliance with ethics requirements
This article does not contain any studies with human or animal subjects.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgement
This work was supported by the National Natural Science Foundation of China (82372507, 82572869, 32401046, and 82172196), the Natural Science Foundation of Hunan Province, China (2023JJ40804, 2024JJ6550), the Open Projects of Key Laboratory of Brain Science Research & Transformation in Tropical Environment of Hainan Province (2023001), the Key Laboratory of Emergency and Trauma (Hainan Medical University) of Ministry of Education, China (KLET-202210), and the Fundamental Research Funds for the Central Universities of Central South University (2026zzts638).
Biographies

Ye He is a MD and PhD candidate of Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. Her current research interests are focused on the roles and mechanisms of PANoptosis in neurodegenerative diseases.

Limin Guo is a PhD candidate of Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. Her researches mainly focus on the pyroptosis in traumatic brain injury.

Lewen Wang is a PhD candidate of Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. Her researches mainly focus on the roles and mechanisms of ferroptosis in glaucoma.

Zixin Li is currently pursuing a master’s degree at Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. Her researches mainly focus on roles of pyroptosis in retinal ischemia-reperfusion injury.

Rui Lu is a research scientist in the lab of Nobel Prize winner Thomas Sudhof, Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, USA. His current research interests are focused on the endocytosis in neuronal polarity.

Xinxing Wan is a research scientist at the Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha, China. His researches mainly focus on regulated cell death in diabetic retinopathy.

Na Liu is a lecturer at the Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. Her current research interests are focused on the interplay between ferroptosis and pyroptosis.

Weitao Yan is a lecturer at the Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. His researches mainly focus on the roles and mechanisms of pyroptosis and ferroptosis in neurodegenerative diseases.

Haifeng Wang is a full professor and head of the Second Hospital of Jilin University, Changchun, China. His researches mainly focus on the injury and repair in neurological diseases.

Qi Zhang is research scientist at the Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. His current research interests are focused on the roles and mechanisms of PANoptosis in neurodegenerative diseases.

Kun Xiong is a full professor and director of the Department of Human Anatomy and Neurobiology, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China. His researches mainly focus on the roles and mechanisms of regulated cell death in damage and repair of neurons.
Contributor Information
Qi Zhang, Email: zhangqi2014@csu.edu.cn.
Kun Xiong, Email: xiongkun2001@163.com.
References
- 1.Quiles J.M., Gustafsson Å.B. The role of mitochondrial fission in cardiovascular health and disease. Nat Rev Cardiol. 2022;19(11):723–736. doi: 10.1038/s41569-022-00703-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Keeney M.T., Rocha E.M., Hoffman E.K., Farmer K., Di Maio R., Weir J., et al. LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson's disease. Sci Transl Med. 2024;16(767):eadl3438 doi: 10.1126/scitranslmed.adl3438. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Park M.W., Cha H.W., Kim J., Kim J.H., Yang H., Yoon S., et al. NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases. Redox Biol. 2021;41 doi: 10.1016/j.redox.2021.101947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Iannielli A., Bido S., Folladori L., Segnali A., Cancellieri C., Maresca A., et al. Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models. Cell Rep. 2018;22(8):2066–2079. doi: 10.1016/j.celrep.2018.01.089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bai M., Cui Y., Sang Z., Gao S., Zhao H., Mei X. Zinc ions regulate mitochondrial quality control in neurons under oxidative stress and reduce PANoptosis in spinal cord injury models via the Lgals3-Bax pathway. Free Radic Biol Med. 2024;221:169–180. doi: 10.1016/j.freeradbiomed.2024.05.037. [DOI] [PubMed] [Google Scholar]
- 6.Lee S., Karki R., Wang Y., Nguyen L.N., Kalathur R.C., Kanneganti T.D. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597(7876):415–419. doi: 10.1038/s41586-021-03875-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Sundaram B., Pandian N., Mall R., Wang Y., Sarkar R., Kim H.J., et al. NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023;186(13) doi: 10.1016/j.cell.2023.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wan H., Ban X., He Y., Yang Y., Hu X., Shang L., et al. Voltage-dependent anion channel 1 oligomerization regulates PANoptosis in retinal ischemia-reperfusion injury. Neural Regen Res. 2025;25 doi: 10.4103/NRR.NRR-D-24-00674. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Sundaram B., Pandian N., Kim H.J., Abdelaal H.M., Mall R., Indari O., et al. NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation. Cell. 2024;187(15) doi: 10.1016/j.cell.2024.05.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wang W., Lu J., Pan N., Zhang H., Dai J., Li J., et al. Identification of early Alzheimer's disease subclass and signature genes based on PANoptosis genes. Front Immunol. 2024;15 doi: 10.3389/fimmu.2024.1462003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zeng Z., You M., Fan C., Rong R., Li H., Xia X. Pathologically high intraocular pressure induces mitochondrial dysfunction through Drp1 and leads to retinal ganglion cell PANoptosis in glaucoma. Redox Biol. 2023;62 doi: 10.1016/j.redox.2023.102687. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Fernandez-Vizarra E., Zeviani M. Mitochondrial disorders of the OXPHOS system. FEBS Lett. 2021;595(8):1062–1106. doi: 10.1002/1873-3468.13995. [DOI] [PubMed] [Google Scholar]
- 13.Chen X., Liu Y., Zhu J., Lei S., Dong Y., Li L., et al. GSK-3β downregulates Nrf2 in cultured cortical neurons and in a rat model of cerebral ischemia-reperfusion. Sci Rep. 2016;6:20196. doi: 10.1038/srep20196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ye Y., Chen A., Li L., Liang Q., Wang S., Dong Q., et al. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification. Kidney Int. 2022;102(6):1259–1275. doi: 10.1016/j.kint.2022.07.034. [DOI] [PubMed] [Google Scholar]
- 15.Li Z., Ran Q., Qu C., Hu S., Cui S., Zhou Y., et al. Sigma-1 receptor activation attenuates DOX-induced cardiotoxicity by alleviating endoplasmic reticulum stress and mitochondrial calcium overload via PERK and IP3R-VDAC1-MCU signaling pathways. Biol Direct. 2025;20(1):23. doi: 10.1186/s13062-025-00617-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Li K., Yang X., Xu T., Shi X., Xu S. Quercetin Protects against Silicon dioxide Particles-induced spleen ZBP1-Mediated PANoptosis by regulating the Nrf2/Drp1/mtDNA axis. Int Immunopharmacol. 2024;143(Pt 3) doi: 10.1016/j.intimp.2024.113546. [DOI] [PubMed] [Google Scholar]
- 17.Liu Y., Huang Y., Xu C., An P., Luo Y., Jiao L., et al. Mitochondrial Dysfunction and Therapeutic Perspectives in Cardiovascular Diseases. Int J Mol Sci. 2022;23(24):16053. doi: 10.3390/ijms232416053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chang X., Niu S., Shang M., Li J., Guo M., Zhang W., et al. ROS-Drp1-mediated mitochondria fission contributes to hippocampal HT22 cell apoptosis induced by silver nanoparticles. Redox Biol. 2023;63 doi: 10.1016/j.redox.2023.102739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Jiajia D., Wen Y., Enyan J., Xiaojian Z., Zhen F., Jia Z., et al. PGAM5 promotes RIPK1-PANoptosome activity by phosphorylating and activating RIPK1 to mediate PANoptosis after subarachnoid hemorrhage in rats. Exp Neurol. 2025;384 doi: 10.1016/j.expneurol.2024.115072. [DOI] [PubMed] [Google Scholar]
- 20.Yamada T., Dawson T.M., Yanagawa T., Iijima M., Sesaki H. SQSTM1/p62 promotes mitochondrial ubiquitination independently of PINK1 and PRKN/parkin in mitophagy. Autophagy. 2019;15(11):2012–2018. doi: 10.1080/15548627.2019.1643185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Che L., Yang C.L., Chen Y., Wu Z.L., Du Z.B., Wu J.S., et al. Mitochondrial redox-driven mitofusin 2 S-glutathionylation promotes neuronal necroptosis via disrupting ER-mitochondria crosstalk in cadmium-induced neurotoxicity. Chemosphere. 2021;262 doi: 10.1016/j.chemosphere.2020.127878. [DOI] [PubMed] [Google Scholar]
- 22.Xu L., Ye Y., Gu W., Xu X., Chen N., Zhang L., et al. Histone lactylation stimulated upregulation of PSMD14 alleviates neuron PANoptosis through deubiquitinating PKM2 to activate PINK1-mediated mitophagy after traumatic brain injury. Autophagy. 2025;1–19 doi: 10.1080/15548627.2025.2471633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Picca A., Faitg J., Auwerx J., Ferrucci L., D’Amico D. Mitophagy in human health, ageing and disease. Nature Metabolism. 2023;5(12):2047–2061. doi: 10.1038/s42255-023-00930-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Liu H., Zhen C., Xie J., Luo Z., Zeng L., Zhao G., et al. TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic mitochondrial DNA. Nat Cell Biol. 2024;26(6):878–891. doi: 10.1038/s41556-024-01419-6. [DOI] [PubMed] [Google Scholar]
- 25.Inigo J.R., Chandra D. The mitochondrial unfolded protein response (UPR(mt)): shielding against toxicity to mitochondria in cancer. J Hematol Oncol. 2022;15(1):98. doi: 10.1186/s13045-022-01317-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Su X., Li Q., Yang M., Zhang W., Liu X., Ba Y., et al. Resveratrol protects against a high-fat diet-induced neuroinflammation by suppressing mitochondrial fission via targeting SIRT1/PGC-1α. Exp Neurol. 2024;380 doi: 10.1016/j.expneurol.2024.114899. [DOI] [PubMed] [Google Scholar]
- 27.Abu Shelbayeh O., Arroum T., Morris S., Busch K.B. PGC-1α is a Master Regulator of Mitochondrial Lifecycle and ROS stress. Response. 2023;12(5):1075 doi: 10.3390/antiox12051075. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Wong J.H., Lai K.O., Barron A.M. Unlocking therapies for neurodegeneration: targeting mitochondrial dysfunction and oxidative stress in Alzheimer’s disease. Curr Opin Physiol. 2026;47 [Google Scholar]
- 29.Fertan E., Rodrigues G.J., Wheeler R.V., Goguen D., Wong A.A., James H., et al. Cognitive Decline, Cerebral-Spleen Tryptophan Metabolism, Oxidative stress, Cytokine Production, and Regulation of the Txnip Gene in a Triple Transgenic Mouse Model of Alzheimer Disease. Am J Pathol. 2019;189(7):1435–1450. doi: 10.1016/j.ajpath.2019.03.006. [DOI] [PubMed] [Google Scholar]
- 30.Lian W., Wang Z., Zhou F., Yuan X., Xia C., Wang W., et al. Cornuside ameliorates cognitive impairments via RAGE/TXNIP/NF-κB signaling in Aβ(1-42) induced Alzheimer's disease mice. J Neuroimmune Pharmacol. 2024;19(1):24. doi: 10.1007/s11481-024-10120-2. [DOI] [PubMed] [Google Scholar]
- 31.Li X., Feng Y., Wang X.X., Truong D., Wu Y.C. The critical Role of SIRT1 in Parkinson's Disease: Mechanism and Therapeutic Considerations. Aging Dis. 2020;11(6):1608–1622. doi: 10.14336/AD.2020.0216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Keeney M.T., Hoffman E.K., Farmer K., Bodle C.R., Fazzari M., Zharikov A., et al. NADPH oxidase 2 activity in Parkinson's disease. Neurobiol Dis. 2022;170 doi: 10.1016/j.nbd.2022.105754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Choi E.-H., Kim M.-H., Park S.-J. Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment. Int J Mol Sci. 2024;25(14):7952. doi: 10.3390/ijms25147952. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Buck S.A., De Miranda B.R., Logan R.W., Fish K.N., Greenamyre J.T., Freyberg Z. VGLUT2 is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration. J Neurosci. 2021;41(22):4937–4947. doi: 10.1523/JNEUROSCI.2770-20.2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mohammed N.N., Tadros M.G., George M.Y. Empagliflozin repurposing in Parkinson's disease; modulation of oxidative stress, neuroinflammation, AMPK/SIRT-1/PGC-1α, and wnt/β-catenin pathways. Inflammopharmacology. 2024;32(1):777–794. doi: 10.1007/s10787-023-01384-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Ahmed S., El-Sayed M.M., Kandeil M.A., Khalaf M.M. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2022;30(6):863–873. doi: 10.1016/j.jsps.2022.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Obrador E., Salvador-Palmer R., López-Blanch R., Jihad-Jebbar A., Vallés S.L., Estrela J.M. The link between Oxidative stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS. Int J Mol Sci. 2021;22(12):6352. doi: 10.3390/ijms22126352. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Bono S., Feligioni M., Corbo M. Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy. Mol Neurodegener. 2021;16(1):71. doi: 10.1186/s13024-021-00479-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Goh C.W., Lee I.C., Sundaram J.R., George S.E., Yusoff P., Brush M.H., et al. Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J Biol Chem. 2018;293(1):163–176. doi: 10.1074/jbc.M117.814111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Zuo X., Zhou J., Li Y., Wu K., Chen Z., Luo Z., et al. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat Struct Mol Biol. 2021;28(2):132–142. doi: 10.1038/s41594-020-00537-7. [DOI] [PubMed] [Google Scholar]
- 41.Zhang Y., Zhou Y.J., Tang J.S., Lan J.Q., Kang Y.Y., Wu L., et al. A comparison study between dimethyl itaconate and dimethyl fumarate in electrophilicity, Nrf2 activation, and anti-inflammation in vitro. J Asian Nat Prod Res. 2022;24(6):577–588. doi: 10.1080/10286020.2021.1949303. [DOI] [PubMed] [Google Scholar]
- 42.Zhao P., Shi W., Ye Y., Xu K., Hu J., Chao H., et al. Atox1 protects hippocampal neurons after traumatic brain injury via DJ-1 mediated anti-oxidative stress and mitophagy. Redox Biol. 2024;72 doi: 10.1016/j.redox.2024.103156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Zhang S., Wu X., Wang J., Shi Y., Hu Q., Cui W., et al. Adiponectin/AdiopR1 signaling prevents mitochondrial dysfunction and oxidative injury after traumatic brain injury in a SIRT3 dependent manner. Redox Biol. 2022;54 doi: 10.1016/j.redox.2022.102390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Xue Q., Kang R., Klionsky D.J., Tang D., Liu J., Chen X. Copper metabolism in cell death and autophagy. Autophagy. 2023;19(8):2175–2195. doi: 10.1080/15548627.2023.2200554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Sadek M.A., Kandil E.A., El Sayed N.S., Sayed H.M., Rabie M.A. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway. Int Immunopharmacol. 2023;115 doi: 10.1016/j.intimp.2022.109647. [DOI] [PubMed] [Google Scholar]
- 46.Noori T., Dehpour A.R., Sureda A., Fakhri S., Sobarzo-Sanchez E., Farzaei M.H., et al. The role of glycogen synthase kinase 3 beta in multiple sclerosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020;132 doi: 10.1016/j.biopha.2020.110874. [DOI] [PubMed] [Google Scholar]
- 47.Chen N.N., Wang J.P., Liu H.F., Zhang M., Zhao Y.Z., Fu X.J., et al. The bone marrow mononuclear cells reduce the oxidative stress of cerebral infarction through PI3K/AKT/NRF2 signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(24):5729–5735. doi: 10.26355/eurrev_201712_14019. [DOI] [PubMed] [Google Scholar]
- 48.Acevedo-Torres K., Berríos L., Rosario N., Dufault V., Skatchkov S., Eaton M.J., et al. Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair. 2009;8(1):126–136. doi: 10.1016/j.dnarep.2008.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Yablonska S., Ganesan V., Ferrando L.M., Kim J., Pyzel A., Baranova O.V., et al. Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23. PNAS. 2019;116(33):16593–16602. doi: 10.1073/pnas.1904101116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Jauhari A., Baranov S.V., Suofu Y., Kim J., Singh T., Yablonska S., et al. Melatonin inhibits cytosolic mitochondrial DNA-induced neuroinflammatory signaling in accelerated aging and neurodegeneration. J Clin Invest. 2020;130(6):3124–3136. doi: 10.1172/JCI135026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Zhang J., Fu X., Jia F., Jing Y., Zhang J., Bai A., et al. Mitochondrial orchestration of PANoptosis: mechanisms, disease pathogenesis, and emerging therapeutic frontiers. Cell Death Discovery. 2025;11(1):476. doi: 10.1038/s41420-025-02750-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Zhang S.H., Liu D., Hu Q., Zhu J., Wang S., Zhou S. Ferulic acid ameliorates pentylenetetrazol-induced seizures by reducing neuron cell death. Epilepsy Res. 2019;156 doi: 10.1016/j.eplepsyres.2019.106183. [DOI] [PubMed] [Google Scholar]
- 53.Millan A., Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res. 2009;151(1):163–170. doi: 10.1016/j.jss.2007.05.020. [DOI] [PubMed] [Google Scholar]
- 54.Zhang Q., Hu X.M., Zhao W.J., Ban X.X., Li Y., Huang Y.X., et al. Targeting Necroptosis: a Novel Therapeutic Option for Retinal Degenerative Diseases. Int J Biol Sci. 2023;19(2):658–674. doi: 10.7150/ijbs.77994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Wang X., Zhou S., Zhang Y., Zhang X., Wu S., Huang Y., et al. TAK1 activates PANoptosis through the NF-κB signalling pathway to delay diabetic wound healing. Burns & trauma. 2026;14 doi: 10.1093/burnst/tkag001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Wang S., Zhang Y., Wang M., Zhai Z., Tan Y., Xu W., et al. Noncanonical feedback loop between “RIP3-MLKL” and “4EBP1-eIF4E” promotes neuronal necroptosis. MedComm. 2025;6(3) doi: 10.1002/mco2.70107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Fritsch M., Günther S.D., Schwarzer R., Albert M.C., Schorn F., Werthenbach J.P., et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683–687. doi: 10.1038/s41586-019-1770-6. [DOI] [PubMed] [Google Scholar]
- 58.Wang Y., Yuan H., Shen D., Liu S., Kong W., Zheng K., et al. Artemisinin attenuated ischemic stroke induced pyroptosis by inhibiting ROS/TXNIP/NLRP3/Caspase-1 signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024;177 doi: 10.1016/j.biopha.2024.116894. [DOI] [PubMed] [Google Scholar]
- 59.Li Z., Liu T., Feng Y., Tong Y., Jia Y., Wang C., et al. PPARγ Alleviates Sepsis-Induced Liver Injury by Inhibiting Hepatocyte Pyroptosis via Inhibition of the ROS/TXNIP/NLRP3 Signaling Pathway. Oxid Med Cell Longev. 2022;2022 doi: 10.1155/2022/1269747. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Park S.Y., Kang H.M., Park G., Oh J.W., Choi Y.W. OGD/R-induced ferroptosis and pyroptosis in retinal pigment epithelium cells: Role of PLD1 and PLD2 modulation. Cell Biochem Funct. 2023;41(8):1162–1173. doi: 10.1002/cbf.3848. [DOI] [PubMed] [Google Scholar]
- 61.Rajesh Y., Kanneganti T.D. Innate Immune Cell Death in Neuroinflammation and Alzheimer's Disease. Cells. 2022;11(12):1885. doi: 10.3390/cells11121885. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Yin W., Zhou Q.L., OuYang S.X., Chen Y., Gong Y.T., Liang Y.M. Uric acid regulates NLRP3/IL-1β signaling pathway and further induces vascular endothelial cells injury in early CKD through ROS activation and K(+) efflux. BMC Nephrol. 2019;20(1):319. doi: 10.1186/s12882-019-1506-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Hughes S.A., Lin M., Weir A., Huang B., Xiong L., Chua N.K., et al. Caspase-8-driven apoptotic and pyroptotic crosstalk causes cell death and IL-1β release in X-linked inhibitor of apoptosis (XIAP) deficiency. EMBO J. 2023;42(5) doi: 10.15252/embj.2021110468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Huang K., Zhang Q., Wan H., Ban X.-X., Chen X.-Y., Wan X.-X., et al. TAK1 at the crossroads of multiple regulated cell death pathways: from molecular mechanisms to human diseases. FEBS J. 2025;25:1–29. doi: 10.1111/febs.70042. [DOI] [PubMed] [Google Scholar]
- 65.Wu S., Shi Y., Jiang L., Bu W., Zhang K., Lin W., et al. N-Acetylcysteine-Derived Carbon Dots for Free Radical Scavenging in Intervertebral Disc Degeneration. Adv Healthc Mater. 2023;12(24) doi: 10.1002/adhm.202300533. [DOI] [PubMed] [Google Scholar]
- 66.Yan W.T., Yang Y.D., Hu X.M., Ning W.Y., Liao L.S., Lu S., et al. Do pyroptosis, apoptosis, and necroptosis (PANoptosis) exist in cerebral ischemia? evidence from cell and rodent studies. Neural Regen Res. 2022;17(8):1761–1768. doi: 10.4103/1673-5374.331539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Özdemir A.Y., Hofbauerová K., Kopecký V., Jr., Novotný J., Rudajev V. Different amyloid β42 preparations induce different cell death pathways in the model of SH-SY5Y neuroblastoma cells. Cell Mol Biol Lett. 2024;29(1):143. doi: 10.1186/s11658-024-00657-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Zhou Q.M., Zhao H.Y., Ma C., Huang L., Liu J., Guo L., et al. Pocahemiketone a, a Sesquiterpenoid Possessing a Spirocyclic Skeleton with a Hemiketal Endoperoxide Unit, Alleviates Aβ(25-35)-Induced Pyroptosis and Oxidative stress in SH-SY5Y Cells. Org Lett. 2022;24(26):4734–4738. doi: 10.1021/acs.orglett.2c01587. [DOI] [PubMed] [Google Scholar]
- 69.Perier C., Bové J., Wu D.-C., Dehay B., Choi D.-K., Jackson-Lewis V., et al. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci. 2007;104(19):8161–8166. doi: 10.1073/pnas.0609874104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Muhammad A.J., Al-baqami F.F., Alanazi F.E., Alattar A., Alshaman R., Rehman N.U., et al. The Interplay of Carveol and All-Trans Retinoic Acid (ATRA) in Experimental Parkinson’s Disease: Role of Inflammasome-Mediated Pyroptosis and Nrf2. Neurochem Res. 2024;49(11):3118–3130. doi: 10.1007/s11064-024-04226-5. [DOI] [PubMed] [Google Scholar]
- 71.Zhao Q., Zhang X., Zhang J., Zhang Y., Jia L., Guo S., et al. Reduction of D2 receptors on microglia leads to ZBP1-mediated PANoptosis of mPFC in Parkinson's disease depression mice. Int Immunopharmacol. 2025;158 doi: 10.1016/j.intimp.2025.114809. [DOI] [PubMed] [Google Scholar]
- 72.Lou J., Mao Y., Jiang W., Shen H., Fan Y., Yu Q., et al. Vol. 11. Advanced science (Weinheim; Baden-Wurttemberg, Germany): 2024. (TRIM56 Modulates YBX1 Degradation to Ameliorate ZBP1-Mediated Neuronal PANoptosis in Spinal Cord Injury). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Jiang D., Yang X., Ge M., Hu H., Xu C., Wen S., et al. Zinc defends against Parthanatos and promotes functional recovery after spinal cord injury through SIRT3-mediated anti-oxidative stress and mitophagy. CNS Neurosci Ther. 2023;29(10):2857–2872. doi: 10.1111/cns.14222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Lyabin D.N., Eliseeva I.A., Ovchinnikov L.P. YB-1 protein: functions and regulation. Wiley Interdiscip Rev: RNA. 2014;5(1):95–110. doi: 10.1002/wrna.1200. [DOI] [PubMed] [Google Scholar]
- 75.Xie L., Wu H., Shi W., Zhang J., Huang X., Yu T. Melatonin Exerts an Anti-Panoptoic Role in Spinal Cord Ischemia-Reperfusion Injured Rats. Advanced biology. 2024;8(1) doi: 10.1002/adbi.202300424. [DOI] [PubMed] [Google Scholar]
- 76.Xie L., Wu H., He Q., Shi W., Zhang J., Xiao X., et al. A slow-releasing donor of hydrogen sulfide inhibits neuronal cell death via anti-PANoptosis in rats with spinal cord ischemia‒reperfusion injury. Cell Commun Signal. 2024;22(1):33. doi: 10.1186/s12964-023-01457-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Tabassum R., Jeong N.Y. Potential for therapeutic use of hydrogen sulfide in oxidative stress-induced neurodegenerative diseases. Int J Med Sci. 2019;16(10):1386–1396. doi: 10.7150/ijms.36516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Yang J.-R., Tan F.-Q., Cheng C.-J., Zhang M.-W., Yu J.-G. Sinomenine ameliorates myocardial ischemia/reperfusion injury by inhibiting mitochondrial oxidative stress-mediated PANoptosis and ferroptosis via α7nAChR. Life Sci. 2026;388 doi: 10.1016/j.lfs.2026.124199. [DOI] [PubMed] [Google Scholar]
- 79.Fan L.F., He P.Y., Peng Y.C., Du Q.H., Ma Y.J., Jin J.X., et al. Mdivi-1 ameliorates early brain injury after subarachnoid hemorrhage via the suppression of inflammation-related blood-brain barrier disruption and endoplasmic reticulum stress-based apoptosis. Free Radic Biol Med. 2017;112:336–349. doi: 10.1016/j.freeradbiomed.2017.08.003. [DOI] [PubMed] [Google Scholar]
- 80.Yu B., Ma J., Li J., Wang D., Wang Z., Wang S. Mitochondrial phosphatase PGAM5 modulates cellular senescence by regulating mitochondrial dynamics. Nat Commun. 2020;11(1):2549. doi: 10.1038/s41467-020-16312-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Chen Y., Gong K., Xu Q., Meng J., Long T., Chang C., et al. Phosphoglycerate Mutase 5 Knockdown Alleviates Neuronal Injury after Traumatic Brain Injury through Drp1-Mediated Mitochondrial Dysfunction. Antioxid Redox Signal. 2021;34(2):154–170. doi: 10.1089/ars.2019.7982. [DOI] [PubMed] [Google Scholar]
- 82.Ma J., Qian S., Ma N., Zhang L., Xu L., Liu X., et al. Effect of short-term 10 Hz repeated transcranial magnetic stimulation on postural control ability in patients with mild hemiparesis in acute ischemic stroke: a single-blinded randomized controlled trial. Front Neurol. 2024;15 doi: 10.3389/fneur.2024.1439904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Zhang K., Wang Z.C., Sun H., Long H., Wang Y. Esculentoside H reduces the PANoptosis and protects the blood-brain barrier after cerebral ischemia/reperfusion through the TLE1/PI3K/AKT signaling pathway. Exp Neurol. 2024;379 doi: 10.1016/j.expneurol.2024.114850. [DOI] [PubMed] [Google Scholar]
- 84.Cheng S., Lu Q., Liu Q., Ma Y., Chen J., Lu D., et al. Synergistic effects of repeated transcranial magnetic stimulation and mesenchymal stem cells transplantation on alleviating neuroinflammation and PANoptosis in cerebral ischemia. J Neuroinflammation. 2024;21(1):311. doi: 10.1186/s12974-024-03302-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Zheng S., Ma M., Chen Y., Li M. Effects of quercetin on ovarian function and regulation of the ovarian PI3K/Akt/FoxO3a signalling pathway and oxidative stress in a rat model of cyclophosphamide-induced premature ovarian failure. Basic Clin Pharmacol Toxicol. 2022;130(2):240–253. doi: 10.1111/bcpt.13696. [DOI] [PubMed] [Google Scholar]
- 86.Lan Z., Tan F., He J., Liu J., Lu M., Hu Z., et al. Curcumin-primed olfactory mucosa-derived mesenchymal stem cells mitigate cerebral ischemia/reperfusion injury-induced neuronal PANoptosis by modulating microglial polarization. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024;129 doi: 10.1016/j.phymed.2024.155635. [DOI] [PubMed] [Google Scholar]
- 87.An H., Shao C., He Y., Zhou H., Wang T., Xu G., et al. Calycosin Inhibit PANoptosis and Alleviate Brain damage: a Bioinformatics and Experimental Verification Approach. ACS Chem Nerosci. 2025;16(8):1550–1564. doi: 10.1021/acschemneuro.5c00072. [DOI] [PubMed] [Google Scholar]
- 88.Yan W.T., Zhao W.J., Hu X.M., Ban X.X., Ning W.Y., Wan H., et al. PANoptosis-like cell death in ischemia/reperfusion injury of retinal neurons. Neural Regen Res. 2023;18(2):357–363. doi: 10.4103/1673-5374.346545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Ye D., Xu Y., Shi Y., Fan M., Lu P., Bai X., et al. Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. J Pineal Res. 2022;73(4) doi: 10.1111/jpi.12828. [DOI] [PubMed] [Google Scholar]
- 90.Kim K.Y., Perkins G.A., Shim M.S., Bushong E., Alcasid N., Ju S., et al. DRP1 inhibition rescues retinal ganglion cells and their axons by preserving mitochondrial integrity in a mouse model of glaucoma. Cell Death Dis. 2015;6(8):e1839. doi: 10.1038/cddis.2015.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Peña-Blanco A., García-Sáez A.J. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 2018;285(3):416–431. doi: 10.1111/febs.14186. [DOI] [PubMed] [Google Scholar]
- 92.Wan H, Yan YD, Hu XM, Shang L, Chen YH, Huang YX, et al. Inhibition of mitochondrial VDAC1 oligomerization alleviates apoptosis and necroptosis of retinal neurons following OGD/R injury. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft. 2023;247:152049. [DOI] [PubMed]
- 93.Kumar P., Osahon O.W., Sekhar R.V. GlyNAC (Glycine and N-Acetylcysteine) Supplementation in mice increases Length of Life by Correcting Glutathione Deficiency, Oxidative stress, Mitochondrial Dysfunction, Abnormalities in Mitophagy and Nutrient Sensing, and Genomic damage. Nutrients. 2022;14(5):e372. doi: 10.3390/nu14051114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Liu M., Gao M., Shi X., Yin Y., Liu H., Xie R., et al. Quercetin attenuates SiO(2)-induced ZBP-1-mediated PANoptosis in mouse neuronal cells via the ROS/TLR4/NF-κb pathway. J Environ Manage. 2024;370 doi: 10.1016/j.jenvman.2024.122948. [DOI] [PubMed] [Google Scholar]
- 95.Kang Y., Yin S., Zhou X., Liu J., Tan X., Zhang C., et al. Intranasal Zinc Oxide Nanoparticles Induce Neuronal PANoptosis via Microglial Pathway. Small. 2025;21(12) doi: 10.1002/smll.202408139. [DOI] [PubMed] [Google Scholar]
- 96.Jing G., Wang H., Nan F., Liu Y., Zhang M. Naofucong Ameliorates High Glucose Induced Hippocampal Neuron Injury through Suppressing P2X7/NLRP1/Caspase-1 Pathway. Front Pharmacol. 2021;12 doi: 10.3389/fphar.2021.647116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Zhao Z., Wang R., Ge H., Hou L., Hatano T., Hattori N., et al. ECHS1-NOX4 interaction suppresses rotenone-induced dopaminergic neurotoxicity through inhibition of mitochondrial ROS production. Free Radic Biol Med. 2025;232:56–71. doi: 10.1016/j.freeradbiomed.2025.02.048. [DOI] [PubMed] [Google Scholar]
- 98.Dutta D., Liu J., Xu E., Xiong H. Methamphetamine Enhancement of HIV-1 gp120-Mediated NLRP3 Inflammasome Activation and Resultant Proinflammatory responses in Rat Microglial Cultures. Int J Mol Sci. 2024;25(7):3588. doi: 10.3390/ijms25073588. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Li H., Guan J., Chen J., Sun W., Chen H., Wen Y., et al. Necroptosis signaling and NLRP3 inflammasome cross-talking in epithelium facilitate Pseudomonas aeruginosa mediated lung injury. Biochim Biophys Acta. 2023;1869(3) doi: 10.1016/j.bbadis.2022.166613. [DOI] [PubMed] [Google Scholar]
- 100.Liu L., Li M.Z., Yao M.H., Yang T.N., Tang Y.X., Li J.L. Melatonin inhibits atrazine-induced mitochondrial impairment in cerebellum of mice: Modulation of cGAS-STING-NLRP3 axis-dependent cell pyroptosis. Sci Total Environ. 2024;912 doi: 10.1016/j.scitotenv.2023.168924. [DOI] [PubMed] [Google Scholar]
- 101.Chunchai T., Pintana H., Arinno A., Ongnok B., Pantiya P., Khuanjing T., et al. Melatonin and metformin counteract cognitive dysfunction equally in male rats with doxorubicin-induced chemobrain. Neurotoxicology. 2023;94:158–171. doi: 10.1016/j.neuro.2022.11.012. [DOI] [PubMed] [Google Scholar]
- 102.Hong C., Wang L., Zhou X., Zou L., Xiang X., Deng H., et al. Protective Effects of Mdivi-1 on Cognition Disturbance following Sepsis in mice via Alleviating Microglia Activation and Polarization. CNS Neurosci Ther. 2025;31(1) doi: 10.1111/cns.70149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Zhan L., Lu Z., Zhu X., Xu W., Li L., Li X., et al. Hypoxic preconditioning attenuates necroptotic neuronal death induced by global cerebral ischemia via Drp1-dependent signaling pathway mediated by CaMKIIα inactivation in adult rats. FASEB J. 2019;33(1):1313–1329. doi: 10.1096/fj.201800111RR. [DOI] [PubMed] [Google Scholar]
- 104.Shteinfer-Kuzmine A., Argueti-Ostrovsky S., Leyton-Jaimes M.F., Anand U., Abu-Hamad S., Zalk R., et al. Targeting the Mitochondrial Protein VDAC1 as a potential Therapeutic Strategy in ALS. Int J Mol Sci. 2022;23(17):9946. doi: 10.3390/ijms23179946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Zheng H.N., Zhang H., Wang J., Jia G.Y., Zhao Z.G., Niu C.Y. Exercise preconditioning improves mesenteric lymphatic contractility through mam in rats following hemorrhagic shock. Shock (Augusta, Ga) 2024;62(5):698–706. doi: 10.1097/SHK.0000000000002424. [DOI] [PubMed] [Google Scholar]
- 106.Ganjam G.K., Bolte K., Matschke L.A., Neitemeier S., Dolga A.M., Höllerhage M., et al. Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons. Cell Death Dis. 2019;10(11):865. doi: 10.1038/s41419-019-2091-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Yang X., Zeng Q., Tezel G. Regulation of distinct caspase-8 functions in retinal ganglion cells and astroglia in experimental glaucoma. Neurobiol Dis. 2021;150 doi: 10.1016/j.nbd.2021.105258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Nuovo G.J., Rice M., Zanesi N., Sawant D., Crilly C., Tili E. The Prevention of Fatal Tauopathy in a Mouse Model of Alzheimer Disease by Blocking BCL2. Applied immunohistochemistry & molecular morphology : AIMM. 2025;33(3):142–151. doi: 10.1097/PAI.0000000000001251. [DOI] [PubMed] [Google Scholar]
- 109.Kim D.Y., Leem Y.H., Park J.S., Park J.E., Park J.M., Kang J.L., et al. RIPK1 Regulates Microglial Activation in Lipopolysaccharide-Induced Neuroinflammation and MPTP-Induced Parkinson's Disease Mouse Models. Cells. 2023;12(3):417. doi: 10.3390/cells12030417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Jinawong K., Apaijai N., Wongsuchai S., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Necrostatin-1 Mitigates Cognitive Dysfunction in Prediabetic Rats with No Alteration in Insulin Sensitivity. Diabetes. 2020;69(7):1411–1423. doi: 10.2337/db19-1128. [DOI] [PubMed] [Google Scholar]
- 111.Wang Y., Jiao J., Zhang S., Zheng C., Wu M. RIP3 inhibition protects locomotion function through ameliorating mitochondrial antioxidative capacity after spinal cord injury. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019;116 doi: 10.1016/j.biopha.2019.109019. [DOI] [PubMed] [Google Scholar]
- 112.Huang Z., Liang J., Chen S., Ng T.K., Brelén M.E., Liu Q., et al. RIP3-mediated microglial necroptosis promotes neuroinflammation and neurodegeneration in the early stages of diabetic retinopathy. Cell Death Dis. 2023;14(3):227. doi: 10.1038/s41419-023-05660-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Jiao J., Wang Y., Ren P., Sun S., Wu M. Necrosulfonamide Ameliorates Neurological Impairment in Spinal Cord Injury by improving Antioxidative Capacity. Front Pharmacol. 2019;10:1538. doi: 10.3389/fphar.2019.01538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Leem Y.H., Kim D.Y., Park J.E., Kim H.S. Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and α-synuclein oligomerization in a subacute MPTP mouse model of Parkinson's disease. Sci Rep. 2023;13(1):8783. doi: 10.1038/s41598-023-35975-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Gordon R., Albornoz E.A., Christie D.C., Langley M.R., Kumar V., Mantovani S., et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10(465):eaah4066 doi: 10.1126/scitranslmed.aah4066. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Wang A., Zhong G., Ying M., Fang Z., Chen Y., Wang H., et al. Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1/Parkin pathway. Neuropharmacology. 2024;257 doi: 10.1016/j.neuropharm.2024.110063. [DOI] [PubMed] [Google Scholar]
- 117.Chang Y.J., Chen C.H., Chen Y.C., Wu M.T., Lin T.Y., Hua K.F., et al. Protective Effects of Antcin H Isolated from Antrodia cinnamomea against Neuroinflammation in Huntington's Disease via NLRP3 Inflammasome Inhibition. J Neuroimmune Pharmacol. 2024;20(1):1. doi: 10.1007/s11481-024-10161-7. [DOI] [PubMed] [Google Scholar]
- 118.Zhang W., Wu C.-c., Ge M.-M., Yuan X.-M., Han S.-Y., Zhao F.-T., et al. The PGC-1α/ERRα/ULK1 pathway contributes to Perioperative neurocognitive disorders by inducing mitochondrial dysfunction and activating NLRP3 inflammasome in aged mice. Neuropharmacology. 2024;260 doi: 10.1016/j.neuropharm.2024.110119. [DOI] [PubMed] [Google Scholar]
- 119.Sun R., Peng M., Xu P., Huang F., Xie Y., Li J., et al. Low-density lipoprotein receptor (LDLR) regulates NLRP3-mediated neuronal pyroptosis following cerebral ischemia/reperfusion injury. J Neuroinflammation. 2020;17(1):330. doi: 10.1186/s12974-020-01988-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Ma X., Hao J., Wu J., Li Y., Cai X., Zheng Y. Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration. Adv Mater. 2022;34(15) doi: 10.1002/adma.202106723. [DOI] [PubMed] [Google Scholar]
- 121.Rust R., Yin H., Achón Buil B., Sagare A.P., Kisler K. The blood–brain barrier: a help and a hindrance. Brain. 2025;148(7):2262–2282. doi: 10.1093/brain/awaf068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Xu Z., Xie Y., Chen W., Deng W. Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions. 2025;6(9) doi: 10.1002/mco2.70337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Ge W., Zhang X., Lin J., Wang Y., Zhang X., Duan Y., et al. Rnd3 protects against doxorubicin-induced cardiotoxicity through inhibition of PANoptosis in a Rock1/Drp1/mitochondrial fission-dependent manner. Cell Death Dis. 2025;16(1):2. doi: 10.1038/s41419-024-07322-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Ye Z., Deng M., Yang Y., Song Y., Weng L., Qi W., et al. Epithelial mitochondrial fission-mediated PANoptosis is crucial for ulcerative colitis and its inhibition by saquinavir through Drp1. Pharmacol Res. 2024;210 doi: 10.1016/j.phrs.2024.107538. [DOI] [PubMed] [Google Scholar]
- 125.Zhang Y., Hu J., Zhang Y., Ci X. Amentoflavone protects against cisplatin-induced acute kidney injury by modulating Nrf2-mediated oxidative stress and ferroptosis and partially by activating Nrf2-dependent PANoptosis. Front Pharmacol. 2025;16 doi: 10.3389/fphar.2025.1508047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126.Tan Y.-T., Li T., Wang R.-B., Liu Z.-K., Ma M.-Y., Huang R.-Z., et al. WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis. Cancer Lett. 2024;604 doi: 10.1016/j.canlet.2024.217254. [DOI] [PubMed] [Google Scholar]
- 127.Kong L., Liu Y., Li J., Wang Y., Ji P., Shi Q., et al. Ginsenoside Rg1 alleviates chronic inflammation-induced neuronal ferroptosis and cognitive impairments via regulation of AIM2 - Nrf2 signaling pathway. J Ethnopharmacol. 2024;330 doi: 10.1016/j.jep.2024.118205. [DOI] [PubMed] [Google Scholar]
- 128.Hu C., Li M., Chen Y., Cheng W., Wang H., Zhou Y., et al. AIM2 regulates autophagy to mitigate oxidative stress in aged mice with acute liver injury. Cell Death Discovery. 2024;10(1):107. doi: 10.1038/s41420-024-01870-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.West A.P., Brodsky I.E., Rahner C., Woo D.K., Erdjument-Bromage H., Tempst P., et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011;472(7344):476–480. doi: 10.1038/nature09973. [DOI] [PMC free article] [PubMed] [Google Scholar]
